| 1 |
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020;5:831-840. [PMID: 32219363 DOI: 10.1001/jamacardio.2020.1286] [Cited by in Crossref: 767] [Cited by in F6Publishing: 667] [Article Influence: 383.5] [Reference Citation Analysis]
|
| 2 |
Simabuco FM, Tamura RE, Pavan ICB, Morale MG, Ventura AM. Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses. Genet Mol Biol 2020;44:e20200212. [PMID: 33237152 DOI: 10.1590/1678-4685-GMB-2020-0212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 3 |
Banda JM, Tekumalla R, Wang G, Yu J, Liu T, Ding Y, Artemova E, Tutubalina E, Chowell G. A Large-Scale COVID-19 Twitter Chatter Dataset for Open Scientific Research—An International Collaboration. Epidemiologia 2021;2:315-24. [DOI: 10.3390/epidemiologia2030024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 4 |
Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, Honoré S, Gaubert JY, Fournier PE, Tissot-Dupont H, Chabrière E, Stein A, Deharo JC, Fenollar F, Rolain JM, Obadia Y, Jacquier A, La Scola B, Brouqui P, Drancourt M, Parola P, Raoult D; IHU COVID-19 Task force. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis 2020;36:101791. [PMID: 32593867 DOI: 10.1016/j.tmaid.2020.101791] [Cited by in Crossref: 130] [Cited by in F6Publishing: 116] [Article Influence: 65.0] [Reference Citation Analysis]
|
| 5 |
Pereira GJDS, Leão AHFF, Erustes AG, Morais IBM, Vrechi TAM, Zamarioli LDS, Pereira CAS, Marchioro LO, Sperandio LP, Lins ÍVF, Piacentini M, Fimia GM, Reckziegel P, Smaili SS, Bincoletto C. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. Int J Mol Sci 2021;22:4067. [PMID: 33920748 DOI: 10.3390/ijms22084067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Curtin N, Bányai K, Thaventhiran J, Le Quesne J, Helyes Z, Bai P. Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol 2020;177:3635-45. [PMID: 32441764 DOI: 10.1111/bph.15137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 7 |
Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, Yu F. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 2021;6:233. [PMID: 34117216 DOI: 10.1038/s41392-021-00653-w] [Reference Citation Analysis]
|
| 8 |
Zhao B, Yang TF, Zheng R. Theory and reality of antivirals against SARS-CoV-2. World J Clin Cases 2021; 9(23): 6663-6673 [PMID: 34447813 DOI: 10.12998/wjcc.v9.i23.6663] [Reference Citation Analysis]
|
| 9 |
Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J 2020;34:6027-37. [PMID: 32350928 DOI: 10.1096/fj.202000919] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 34.5] [Reference Citation Analysis]
|
| 10 |
Cafiero C, Re A, Micera A, Palmirotta R, Monaco D, Romano F, Fabrizio C, Di Francia R, Cacciamani A, Surico PL, D'Amato G, Pisconti S. Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. Pharmgenomics Pers Med 2020;13:463-84. [PMID: 33116761 DOI: 10.2147/PGPM.S270069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Rivera-Izquierdo M, Valero-Ubierna MDC, R-delAmo JL, Fernández-García MÁ, Martínez-Diz S, Tahery-Mahmoud A, Rodríguez-Camacho M, Gámiz-Molina AB, Barba-Gyengo N, Gámez-Baeza P, Cabrero-Rodríguez C, Guirado-Ruiz PA, Martín-Romero DT, Láinez-Ramos-Bossini AJ, Sánchez-Pérez MR, Mancera-Romero J, García-Martín M, Martín-delosReyes LM, Martínez-Ruiz V, Jiménez-Mejías E. [Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality]. Med Clin (Barc) 2020;155:375-81. [PMID: 32773165 DOI: 10.1016/j.medcli.2020.06.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Wang N, Han S, Liu R, Meng L, He H, Zhang Y, Wang C, Lv Y, Wang J, Li X, Ding Y, Fu J, Hou Y, Lu W, Ma W, Zhan Y, Dai B, Zhang J, Pan X, Hu S, Gao J, Jia Q, Zhang L, Ge S, Wang S, Liang P, Hu T, Lu J, Wang X, Zhou H, Ta W, Wang Y, Lu S, He L. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. Phytomedicine 2020;79:153333. [PMID: 32920291 DOI: 10.1016/j.phymed.2020.153333] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 13 |
Jannelli E, Castelli A, Ferranti Calderoni E, Annunziata S, Maccario G, Ivone A, Pasta G, Mosconi M. Fractures in Patients With COVID-19 Infection: Early Prognosis and Management. A Case Series of 20 Patients in a Single Institution in Lombardy, Northern Italy. J Orthop Trauma 2020;34:e389-97. [PMID: 32947590 DOI: 10.1097/BOT.0000000000001905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Grygiel-Górniak B. Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. Clin Rheumatol 2021. [PMID: 34218393 DOI: 10.1007/s10067-021-05805-5] [Reference Citation Analysis]
|
| 15 |
Beus M, Persoons L, Daelemans D, Schols D, Savijoki K, Varmanen P, Yli-Kauhaluoma J, Pavić K, Zorc B. Anthranilamides with quinoline and β-carboline scaffolds: design, synthesis, and biological activity. Mol Divers 2022. [PMID: 34997441 DOI: 10.1007/s11030-021-10347-8] [Reference Citation Analysis]
|
| 16 |
Schrezenmeier EV, Burmester GR, Eckardt K, Dörner T. Role for antimalarials in the management of COVID-19. Current Opinion in Rheumatology 2020;32:449-57. [DOI: 10.1097/bor.0000000000000731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Richard SA, Kampo S, Esquijarosa Hechavarria M. Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review. Hematol Rep 2020;12:8630. [PMID: 33324480 DOI: 10.4081/hr.2020.8630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Tripathy JP. Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India? J Med Virol 2020;92:1391-3. [PMID: 32330312 DOI: 10.1002/jmv.25933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Younis NK, Zareef RO, Maktabi MAN, Mahfouz R. The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. Genet Test Mol Biomarkers 2021;25:85-101. [PMID: 33596144 DOI: 10.1089/gtmb.2020.0227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
An X, Duan L, Zhang YH, Jin, Zhao S, Zhou RR, Duan Y, Lian F, Tong X. The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19. Chin Med 2021;16:44. [PMID: 34099015 DOI: 10.1186/s13020-021-00454-x] [Reference Citation Analysis]
|
| 21 |
Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir Med 2021;176:106239. [PMID: 33246294 DOI: 10.1016/j.rmed.2020.106239] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 22 |
Hathout RM, Abdelhamid SG, Metwally AA. Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. Inform Med Unlocked 2020;21:100446. [PMID: 33052313 DOI: 10.1016/j.imu.2020.100446] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 23 |
Chang R, Sun WZ. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. Drug Discov Today 2020:S1359-6446(20)30258-0. [PMID: 32629169 DOI: 10.1016/j.drudis.2020.06.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 24 |
Bara GA, de Ridder D, Maciaczyk J. Can neuromodulation support the fight against the COVID19 pandemic? Transcutaneous non-invasive vagal nerve stimulation as a potential targeted treatment of fulminant acute respiratory distress syndrome. Med Hypotheses 2020;143:110093. [PMID: 33017913 DOI: 10.1016/j.mehy.2020.110093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448. [PMID: 32353634 DOI: 10.1016/j.clim.2020.108448] [Cited by in Crossref: 254] [Cited by in F6Publishing: 222] [Article Influence: 127.0] [Reference Citation Analysis]
|
| 26 |
Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol 2020;883:173372. [PMID: 32682787 DOI: 10.1016/j.ejphar.2020.173372] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 27 |
Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother 2021;142:112015. [PMID: 34388532 DOI: 10.1016/j.biopha.2021.112015] [Reference Citation Analysis]
|
| 28 |
Li L, Li R, Wu Z, Yang X, Zhao M, Liu J, Chen D. Therapeutic strategies for critically ill patients with COVID-19. Ann Intensive Care 2020;10:45. [PMID: 32307593 DOI: 10.1186/s13613-020-00661-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 29 |
Fathi M, Vakili K, Sayehmiri F, Mohamadkhani A, Hajiesmaeili M, Rezaei-Tavirani M, Eilami O. The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS One 2021;16:e0246190. [PMID: 33592019 DOI: 10.1371/journal.pone.0246190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 30 |
Singh JA, Ravinetto R. COVID-19 therapeutics: how to sow confusion and break public trust during international public health emergencies. J Pharm Policy Pract 2020;13:47. [PMID: 32719731 DOI: 10.1186/s40545-020-00244-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 31 |
Mohan B, Muhammad S, Al‐sehemi AG, Bharti S, Kumar S, Choudhary M. Synthesis of Copper(II) Coordination Complex, Its Molecular Docking and Computational Exploration for Novel Functional Properties: A Dual Approach. ChemistrySelect 2021;6:738-45. [DOI: 10.1002/slct.202003738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 32 |
Khedkar PH, Patzak A. SARS-CoV-2: What do we know so far? Acta Physiol (Oxf) 2020;229:e13470. [PMID: 32220035 DOI: 10.1111/apha.13470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 33 |
Kumar N, Awasthi A, Kumari A, Sood D, Jain P, Singh T, Sharma N, Grover A, Chandra R. Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis. J Biomol Struct Dyn 2020;:1-16. [PMID: 32815796 DOI: 10.1080/07391102.2020.1808072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 34 |
Ağagündüz D, Çelik MN, Çıtar Dazıroğlu ME, Capasso R. Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. Nutrients 2021;13:1550. [PMID: 34064534 DOI: 10.3390/nu13051550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 35 |
D'Marco L, Puchades MJ, Romero-Parra M, Gimenez-Civera E, Soler MJ, Ortiz A, Gorriz JL. Coronavirus disease 2019 in chronic kidney disease. Clin Kidney J 2020;13:297-306. [PMID: 32699615 DOI: 10.1093/ckj/sfaa104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 36 |
Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, Wurtz N, Rolain JM, Colson P, La Scola B, Raoult D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228. [PMID: 32344177 DOI: 10.1016/j.micpath.2020.104228] [Cited by in Crossref: 138] [Cited by in F6Publishing: 113] [Article Influence: 69.0] [Reference Citation Analysis]
|
| 37 |
Koneru G, Batiha GE, Algammal AM, Mabrok M, Magdy S, Sayed S, AbuElmagd ME, Elnemr R, Saad MM, Abd Ellah NH, Hosni A, Muhammad K, Hetta HF. BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander? Infect Drug Resist 2021;14:1169-84. [PMID: 33790587 DOI: 10.2147/IDR.S300162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 38 |
Mustafa MI, Abdelmoneim AH, Mahmoud EM, Makhawi AM. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors. Mediators Inflamm. 2020;2020:8198963. [PMID: 33029105 DOI: 10.1155/2020/8198963] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 39 |
Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. Front Immunol 2020;11:1439. [PMID: 32655577 DOI: 10.3389/fimmu.2020.01439] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 40 |
Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J 2020;96:550-5. [PMID: 32295814 DOI: 10.1136/postgradmedj-2020-137785] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 29.5] [Reference Citation Analysis]
|
| 41 |
Lecuit M. Chloroquine and COVID-19, where do we stand? Med Mal Infect 2020;50:229-30. [PMID: 32217166 DOI: 10.1016/j.medmal.2020.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 42 |
Bertoli F, Veritti D, Danese C, Samassa F, Sarao V, Rassu N, Gambato T, Lanzetta P. Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. J Ophthalmol 2020;2020:4827304. [PMID: 32963819 DOI: 10.1155/2020/4827304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 43 |
Bhandari R, Khanna G, Kuhad A. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic. Eur J Pharmacol 2021;890:173643. [PMID: 33065092 DOI: 10.1016/j.ejphar.2020.173643] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 44 |
Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents 2020;56:106054. [PMID: 32534188 DOI: 10.1016/j.ijantimicag.2020.106054] [Cited by in Crossref: 84] [Cited by in F6Publishing: 65] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 45 |
Mahmoud MH, Alghamdi FA, Alghamdi GA, Alkhotani LA, Alrehaili MA, El-Deeb DK. Study of Post-COVID-19 Syndrome in Saudi Arabia. Cureus 2021;13:e17787. [PMID: 34659998 DOI: 10.7759/cureus.17787] [Reference Citation Analysis]
|
| 46 |
Mslati H, Gentile F, Perez C, Cherkasov A. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. J Chem Inf Model 2021;61:3771-88. [PMID: 34313439 DOI: 10.1021/acs.jcim.1c00384] [Reference Citation Analysis]
|
| 47 |
Pérez-Belmonte LM, López-Carmona MD, Quevedo-Marín JL, Ricci M, Martín-Carmona J, Sanz-Cánovas J, López-Sampalo A, Martín-Escalante MD, Bernal-López MR, Gómez-Huelgas R. Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. Int J Environ Res Public Health 2020;17:E6845. [PMID: 32961675 DOI: 10.3390/ijerph17186845] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 48 |
Achilonu I, Iwuchukwu EA, Achilonu OJ, Fernandes MA, Sayed Y. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. J Mol Graph Model 2020;101:107730. [PMID: 32920239 DOI: 10.1016/j.jmgm.2020.107730] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 49 |
Mohapatra S, Nath P, Chatterjee M, Das N, Kalita D, Roy P, Satapathi S. Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking. PLoS One 2020;15:e0241543. [PMID: 33180803 DOI: 10.1371/journal.pone.0241543] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 50 |
Olaimat AN, Aolymat I, Shahbaz HM, Holley RA. Knowledge and Information Sources About COVID-19 Among University Students in Jordan: A Cross-Sectional Study. Front Public Health 2020;8:254. [PMID: 32574314 DOI: 10.3389/fpubh.2020.00254] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 51 |
Lai YJ, Chang CM, Lin CK, Yang YP, Chien CS, Wang PH, Chang CC. Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. J Chin Med Assoc 2020;83:812-6. [PMID: 32902940 DOI: 10.1097/JCMA.0000000000000362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 52 |
Maia P, Justi R, Santos M. Aspects About Science in the Context of Production and Communication of Knowledge of COVID-19. Sci Educ (Dordr) 2021;:1-24. [PMID: 33897109 DOI: 10.1007/s11191-021-00229-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med 2021;289:147-61. [PMID: 32696489 DOI: 10.1111/joim.13144] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 26.5] [Reference Citation Analysis]
|
| 54 |
Sportelli MC, Izzi M, Kukushkina EA, Hossain SI, Picca RA, Ditaranto N, Cioffi N. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2? Nanomaterials (Basel) 2020;10:E802. [PMID: 32326343 DOI: 10.3390/nano10040802] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 40.5] [Reference Citation Analysis]
|
| 55 |
Li YP, Ma Y, Wang N, Jin ZB. Eyes on coronavirus. Stem Cell Res 2021;51:102200. [PMID: 33535156 DOI: 10.1016/j.scr.2021.102200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 56 |
Hu K, Lin L, Liang Y, Shao X, Hu Z, Luo H, Lei M. COVID-19: risk factors for severe cases of the Delta variant. Aging (Albany NY) 2021;13:23459-70. [PMID: 34710058 DOI: 10.18632/aging.203655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Chowdhury SF, Sium SMA, Anwar S. Research and Management of Rare Diseases in the COVID-19 Pandemic Era: Challenges and Countermeasures. Front Public Health 2021;9:640282. [PMID: 33937170 DOI: 10.3389/fpubh.2021.640282] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 58 |
Rufaida, Mahmood T, Kedwai I, Ahsan F, Shamim A, Shariq M, Parveen S. A dossier on COVID-19 chronicle. J Basic Clin Physiol Pharmacol 2021. [PMID: 34280963 DOI: 10.1515/jbcpp-2020-0511] [Reference Citation Analysis]
|
| 59 |
Khan JZ, Ali I, Hassan Z. Repurposed Drugs Against COVID-19: Safety Concerns and Stockout. Hosp Pharm 2020;55:218-9. [PMID: 32742008 DOI: 10.1177/0018578720925387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 60 |
Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Intern Emerg Med 2021;16:281-308. [PMID: 33398609 DOI: 10.1007/s11739-020-02569-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 61 |
Zhirnov OP. Molecular Targets in the Chemotherapy of Coronavirus Infection.Biochemistry (Mosc). 2020;85:523-530. [PMID: 32571182 DOI: 10.1134/S0006297920050016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Bolarin JA, Oluwatoyosi MA, Orege JI, Ayeni EA, Ibrahim YA, Adeyemi SB, Tiamiyu BB, Gbadegesin LA, Akinyemi TO, Odoh CK, Umeobi HI, Adeoye AB. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. Int Immunopharmacol 2021;90:107228. [PMID: 33302035 DOI: 10.1016/j.intimp.2020.107228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 63 |
Mollaeian A, Kim DS, Haas CJ. COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. TORJ 2021;15:69-76. [DOI: 10.2174/1874312902115010069] [Reference Citation Analysis]
|
| 64 |
Lundstrom K. Coronavirus Pandemic-Therapy and Vaccines. Biomedicines 2020;8:E109. [PMID: 32375268 DOI: 10.3390/biomedicines8050109] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 65 |
Ghareeb DA, Saleh SR, Nofal MS, Kaddah MMY, Hassan SF, Seif IK, El-zahaby SA, Khedr SM, Kenawy MY, Masoud AA, Soudi SA, Sobhy AA, Sery JG, El-wahab MGA, Elmoneam AAA, Al-mahallawi AM, El-demellawy MA. Potential therapeutic and pharmacological strategies for SARS-CoV2. J Pharm Investig 2021;51:281-96. [DOI: 10.1007/s40005-021-00520-4] [Reference Citation Analysis]
|
| 66 |
Rivera-Izquierdo M, Valero-Ubierna MDC, R-delAmo JL, Fernández-García MÁ, Martínez-Diz S, Tahery-Mahmoud A, Rodríguez-Camacho M, Gámiz-Molina AB, Barba-Gyengo N, Gámez-Baeza P, Cabrero-Rodríguez C, Guirado-Ruiz PA, Martín-Romero DT, Láinez-Ramos-Bossini AJ, Sánchez-Pérez MR, Mancera-Romero J, García-Martín M, Martín-delosReyes LM, Martínez-Ruiz V, Jiménez-Mejías E. Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. Med Clin (Engl Ed) 2020;155:375-81. [PMID: 33072869 DOI: 10.1016/j.medcle.2020.06.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 67 |
Kumar P, Sah AK, Tripathi G, Kashyap A, Tripathi A, Rao R, Mishra PC, Mallick K, Husain A, Kashyap MK. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Mol Cell Biochem 2021;476:553-74. [PMID: 33029696 DOI: 10.1007/s11010-020-03924-2] [Reference Citation Analysis]
|
| 68 |
Licata A, Minissale MG, Distefano M, Montalto G. Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know? GastroHep 2021;3:121-30. [PMID: 34149320 DOI: 10.1002/ygh2.455] [Reference Citation Analysis]
|
| 69 |
Abayomi A, Osibogun A, Ezechi O, Wright K, Ola B, Ojo O, Kuyinu Y, Zamba E, Abdur-Razzaq H, Erinoso OA, Anya SE. A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial. Trials 2021;22:869. [PMID: 34863267 DOI: 10.1186/s13063-021-05675-x] [Reference Citation Analysis]
|
| 70 |
Sutanto H, Heijman J. Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. Front Physiol 2020;11:587709. [PMID: 33192602 DOI: 10.3389/fphys.2020.587709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 71 |
Qureshi U, Mir S, Naz S, Nur-E-Alam M, Ahmed S, Ul-Haq Z. Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications. J Biomol Struct Dyn 2021;:1-12. [PMID: 33950784 DOI: 10.1080/07391102.2021.1906750] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 72 |
Al-Shuhaib MBS, Hashim HO, Al-Shuhaib JMB. Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study. Comput Biol Med 2021;141:105155. [PMID: 34942397 DOI: 10.1016/j.compbiomed.2021.105155] [Reference Citation Analysis]
|
| 73 |
García-Pérez BE, González-Rojas JA, Salazar MI, Torres-Torres C, Castrejón-Jiménez NS. Taming the Autophagy as a Strategy for Treating COVID-19. Cells 2020;9:E2679. [PMID: 33322168 DOI: 10.3390/cells9122679] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 74 |
Pillat MM, Krüger A, Guimarães LMF, Lameu C, de Souza EE, Wrenger C, Ulrich H. Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. Cytometry A 2020;97:872-81. [PMID: 32686260 DOI: 10.1002/cyto.a.24190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 75 |
Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, Ng LPW, Wong YKE, Pei XM, Li MJW, Wong SC. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2020;1-12. [PMID: 33306423 DOI: 10.1080/14787210.2021.1863146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 76 |
Singh S, Ahirwar AK, Asia P, Gopal N, Kaim K, Ahirwar P. COVID-19 and neurology perspective. Horm Mol Biol Clin Investig 2021;42:69-75. [PMID: 33617700 DOI: 10.1515/hmbci-2020-0069] [Reference Citation Analysis]
|
| 77 |
Yamin M. Counting the cost of COVID-19. Int J Inf Technol 2020;:1-7. [PMID: 32412538 DOI: 10.1007/s41870-020-00466-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 78 |
Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, Bobbio-Pallavicini F, Murgo A, Balduzzi S, Caporali R, Montecucco C. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther 2020;22:290. [PMID: 33380344 DOI: 10.1186/s13075-020-02395-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 79 |
Mascolo A, Scavone C, Rafaniello C, Ferrajolo C, Racagni G, Berrino L, Paolisso G, Rossi F, Capuano A. Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. Front Cardiovasc Med 2020;7:143. [PMID: 32850989 DOI: 10.3389/fcvm.2020.00143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 80 |
Piszczatoski CR, Powell J. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. Ann Pharmacother 2020;54:827-31. [PMID: 32389025 DOI: 10.1177/1060028020925558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 81 |
Gong Y, Ma TC, Xu YY, Yang R, Gao LJ, Wu SH, Li J, Yue ML, Liang HG, He X, Yun T. Early Research on COVID-19: A Bibliometric Analysis. Innovation (N Y) 2020;1:100027. [PMID: 32914141 DOI: 10.1016/j.xinn.2020.100027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 82 |
Douche D, Sert Y, Brandán SA, Kawther AA, Bilmez B, Dege N, Louzi AE, Bougrin K, Karrouchi K, Himmi B. 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol as potential antiviral SARS-CoV-2 candidate: Synthesis, crystal structure, Hirshfeld surface analysis, DFT and molecular docking studies. J Mol Struct 2021;1232:130005. [PMID: 33526951 DOI: 10.1016/j.molstruc.2021.130005] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 83 |
Kumari P, Rawat K, Saha L. Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. Curr Pharmacol Rep 2020;:1-13. [PMID: 32837854 DOI: 10.1007/s40495-020-00226-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 84 |
Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens RW, Razonable RR. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). Mayo Clin Proc. 2020;95:1454-1466. [PMID: 32561148 DOI: 10.1016/j.mayocp.2020.04.027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 85 |
van Rensburg R, Pillay-Fuentes Lorente V, Decloedt EH. Current evidence for directed and supportive investigational therapies against COVID-19. Afr J Thorac Crit Care Med 2020;26. [PMID: 34235422 DOI: 10.7196/AJTCCM.2020.v26i2.072] [Reference Citation Analysis]
|
| 86 |
Hussien MA, Abdelaziz AEM. Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease. Netw Model Anal Health Inform Bioinform 2020;9:56. [PMID: 32834922 DOI: 10.1007/s13721-020-00263-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 87 |
Kumar S, Mishra S, Singh SK. Deep Transfer Learning-Based COVID-19 Prediction Using Chest X-Rays. Journal of Health Management 2021;23:730-46. [DOI: 10.1177/09720634211050425] [Reference Citation Analysis]
|
| 88 |
Kim EJ, Coppa K, Hirsch JS, Abrahams S, Johnson J, Lesser M, Davidson KW, Conigliaro J; Northwell Health COVID-19 Research Consortium., Northwell Health COVID-19 Research Consortium. Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York. BMJ Open 2021;11:e042965. [PMID: 33558355 DOI: 10.1136/bmjopen-2020-042965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 89 |
Cour M, Amaz C, Bohé J, Rimmelé T, Ovize M, Argaud L. Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis. Ann Transl Med 2021;9:524. [PMID: 33987222 DOI: 10.21037/atm-20-7811] [Reference Citation Analysis]
|
| 90 |
Jafari Porzani S, Konur O, Nowruzi B. Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19. J Biomol Struct Dyn 2021;:1-17. [PMID: 33749496 DOI: 10.1080/07391102.2021.1899050] [Reference Citation Analysis]
|
| 91 |
Teimury A, Mahmoodi Khaledi E. Current Options in the Treatment of COVID-19: A Review. Risk Manag Healthc Policy 2020;13:1999-2010. [PMID: 33116980 DOI: 10.2147/RMHP.S265030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 92 |
Wang Y, Mao JM, Wang GD, Luo ZP, Yang L, Yao Q, Chen KP. Human SARS-CoV-2 has evolved to reduce CG dinucleotide in its open reading frames. Sci Rep 2020;10:12331. [PMID: 32704018 DOI: 10.1038/s41598-020-69342-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 93 |
Arıkan H, Karadoğan D, Tokgöz Akyıl F, Yüksel A, Töreyin ZN, Gürkan CG, Marim F, Eyüboğlu TŞ, Emiralioğlu N, Gürsoy TR, Şerifoğlu İ, Sandal A, Öncel A, Er B, Köse N, Esendağlı D, Hızal M, Er AB, Günaydın FE, Kaya İ, Özakıncı H, Sertçelik ÜÖ, Tuğlu HÇ, Özürk NAA, Ataoğlu Ö, Çakır AC, Toptay H, Erçelik M, Develi E, Çelik S, Karakaş FG, Yıldırım H, Güven DK, Çetin N, Küçükyurt SNA, Elverişli MF, Gülhan PY, Akgün M. COVID-19 Treatment at a Glance. Turk Thorac J 2020;21:438-45. [PMID: 33352100 DOI: 10.5152/TurkThoracJ.2020.20125] [Reference Citation Analysis]
|
| 94 |
Jain S, Potschka H, Chandra PP, Tripathi M, Vohora D. Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. Epilepsy Res 2021;174:106675. [PMID: 34044300 DOI: 10.1016/j.eplepsyres.2021.106675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 95 |
Micallef S, Piscopo TV, Casha R, Borg D, Vella C, Zammit MA, Borg J, Mallia D, Farrugia J, Vella SM, Xerri T, Portelli A, Fenech M, Fsadni C, Mallia Azzopardi C. The first wave of COVID-19 in Malta; a national cross-sectional study. PLoS One 2020;15:e0239389. [PMID: 33057434 DOI: 10.1371/journal.pone.0239389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 96 |
Umar HI, Josiah SS, Saliu TP, Jimoh TO, Ajayi A, Danjuma JB. In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. J Taibah Univ Med Sci 2021;16:162-76. [PMID: 33437230 DOI: 10.1016/j.jtumed.2020.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 97 |
Mazhar F, Hadi MA, Kow CS, Marran AMN, Merchant HA, Hasan SS. Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? Int J Infect Dis 2020;101:107-20. [PMID: 33007453 DOI: 10.1016/j.ijid.2020.09.1470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 98 |
Bongiovanni A, Cusimano A, Annunziata I, d'Azzo A. Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. FASEB Bioadv 2021;3:192-7. [PMID: 33733058 DOI: 10.1096/fba.2020-00073] [Reference Citation Analysis]
|
| 99 |
Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? Int J Antimicrob Agents 2020;56:106078. [PMID: 32629115 DOI: 10.1016/j.ijantimicag.2020.106078] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 100 |
Chavez S, Long B, Koyfman A, Liang SY. Coronavirus Disease (COVID-19): A primer for emergency physicians. Am J Emerg Med 2021;44:220-9. [PMID: 32265065 DOI: 10.1016/j.ajem.2020.03.036] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 40.5] [Reference Citation Analysis]
|
| 101 |
Khodashahi R, Naderi H, Bojdy A, Khodashahi M. Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. CRMR 2021;16:165-83. [DOI: 10.2174/1573398x16999201202121247] [Reference Citation Analysis]
|
| 102 |
Li M, Chen S, Xiang X, Wang Q, Liu X. Effects of SARS-CoV-2 and its functional receptor ACE2 on the cardiovascular system. Herz 2020;45:659-62. [PMID: 33025029 DOI: 10.1007/s00059-020-04989-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 103 |
Khan MM, Noor A, Madni A, Shafiq M. Emergence of novel coronavirus and progress toward treatment and vaccine. Rev Med Virol 2020;30:e2116. [PMID: 32495979 DOI: 10.1002/rmv.2116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 104 |
Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents 2020;55:105988. [PMID: 32305587 DOI: 10.1016/j.ijantimicag.2020.105988] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 105 |
[DOI: 10.1101/2020.04.23.20077065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 106 |
Muchtaridi M, Fauzi M, Khairul Ikram NK, Mohd Gazzali A, Wahab HA. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. Molecules 2020;25:E3980. [PMID: 32882868 DOI: 10.3390/molecules25173980] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 107 |
Luo YH, Chiu HY, Weng CS, Chen YM. Overview of coronavirus disease 2019: Treatment updates and advances. J Chin Med Assoc 2020;83:805-8. [PMID: 32520770 DOI: 10.1097/JCMA.0000000000000367] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 108 |
Guner R, Hasanoglu I, Kayaaslan B, Aypak A, Akinci E, Bodur H, Eser F, Kaya Kalem A, Kucuksahin O, Ates I, Bastug A, Tezer Tekce Y, Bilgic Z, Gursoy FM, Akca HN, Izdes S, Erdem D, Asfuroglu E, Hezer H, Kilic H, Cıvak M, Aydogan S, Buzgan T. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. J Infect Public Health 2021;14:365-70. [PMID: 33647553 DOI: 10.1016/j.jiph.2020.12.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 109 |
Thomas DL. Caring for patients in a new pandemic: the necessity and challenges of observational research. J Clin Invest 2020;130:6225-7. [PMID: 32902413 DOI: 10.1172/JCI143292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 110 |
Moccia F, Gerbino A, Lionetti V, Miragoli M, Munaron LM, Pagliaro P, Pasqua T, Penna C, Rocca C, Samaja M, Angelone T. COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. Geroscience 2020;42:1021-49. [PMID: 32430627 DOI: 10.1007/s11357-020-00198-w] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 111 |
Sood S, Aggarwal V, Aggarwal D, Upadhyay SK, Sak K, Tuli HS, Kumar M, Kumar J, Talwar S. COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. Curr Pharmacol Rep 2020;:1-16. [PMID: 32837855 DOI: 10.1007/s40495-020-00229-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 112 |
Bik E, Mateuszuk L, Orleanska J, Baranska M, Chlopicki S, Majzner K. Chloroquine-Induced Accumulation of Autophagosomes and Lipids in the Endothelium. Int J Mol Sci 2021;22:2401. [PMID: 33673688 DOI: 10.3390/ijms22052401] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 113 |
Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis 2020;23:613-9. [PMID: 32281213 DOI: 10.1111/1756-185X.13842] [Cited by in Crossref: 64] [Cited by in F6Publishing: 40] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 114 |
Lu QB. Reaction Cycles of Halogen Species in the Immune Defense: Implications for Human Health and Diseases and the Pathology and Treatment of COVID-19. Cells 2020;9:E1461. [PMID: 32545714 DOI: 10.3390/cells9061461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 115 |
Caputo L, Lentini G, Habtemariam S. Repurposing therapeutic agents and herbal medicines to defeat viral nemesis. Drug Dev Res 2020;81:641-2. [PMID: 32227604 DOI: 10.1002/ddr.21668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 116 |
Mansouri K, Rastegari-Pouyani M, Ghanbri-Movahed M, Safarzadeh M, Kiani S, Ghanbari-Movahed Z. Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational. Biomed Pharmacother 2020;131:110694. [PMID: 32920511 DOI: 10.1016/j.biopha.2020.110694] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 117 |
[DOI: 10.1101/2020.04.23.20076471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 118 |
Liu Y, Fu X, Xie C. Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22031. [PMID: 32925737 DOI: 10.1097/MD.0000000000022031] [Reference Citation Analysis]
|
| 119 |
Sessa A, Mazzola A, Lim C, Atif M, Pappatella J, Pourcher V, Scatton O, Conti F. COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report. World J Gastroenterol 2020; 26(44): 7076-7084 [PMID: 33311951 DOI: 10.3748/wjg.v26.i44.7076] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 120 |
Lindholm PF, Ramsey G, Kwaan HC. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. Semin Thromb Hemost 2020;46:796-803. [PMID: 32526774 DOI: 10.1055/s-0040-1712157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 121 |
Mathian A, Amoura Z. Response to: ‘Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’’ by Nikpour et al. Ann Rheum Dis 2021;80:e34-e34. [DOI: 10.1136/annrheumdis-2020-217875] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 122 |
Kumar Barman R, Mukhopadhyay A, Maulik U, Das S. A network biology approach to identify crucial host targets for COVID-19. Methods 2022. [DOI: 10.1016/j.ymeth.2022.03.016] [Reference Citation Analysis]
|
| 123 |
Carlotti APCP, Carvalho WB, Johnston C, Rodriguez IS, Delgado AF. COVID-19 Diagnostic and Management Protocol for Pediatric Patients. Clinics (Sao Paulo) 2020;75:e1894. [PMID: 32321116 DOI: 10.6061/clinics/2020/e1894] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 124 |
Feyaerts AF, Luyten W. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? Nutrition 2020;79-80:110948. [PMID: 32911430 DOI: 10.1016/j.nut.2020.110948] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 125 |
Cui C, Zhang M, Yao X, Tu S, Hou Z, Jie En VS, Xiang X, Lin J, Cai T, Shen N, Song C, Qiao J, Zhang S, Li H, Liu D. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Acta Pharm Sin B 2020;10:1216-27. [PMID: 32834950 DOI: 10.1016/j.apsb.2020.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 126 |
Sheervalilou R, Shirvaliloo M, Dadashzadeh N, Shirvalilou S, Shahraki O, Pilehvar-Soltanahmadi Y, Ghaznavi H, Khoei S, Nazarlou Z. COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease. J Cell Physiol. 2020;235:8873-8924. [PMID: 32452539 DOI: 10.1002/jcp.29735] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 127 |
Castelli V, Cimini A, Ferri C. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in". Front Immunol. 2020;11:2132. [PMID: 32983172 DOI: 10.3389/fimmu.2020.02132] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 128 |
Panahi Y, Dadkhah M, Talei S, Gharari Z, Asghariazar V, Abdolmaleki A, Matin S, Molaei S. Can anti-parasitic drugs help control COVID-19? Future Virol 2022. [PMID: 35359702 DOI: 10.2217/fvl-2021-0160] [Reference Citation Analysis]
|
| 129 |
Singh AK, Singh A, Singh R, Misra A. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes Metab Syndr. 2020;14:641-648. [PMID: 32428865 DOI: 10.1016/j.dsx.2020.05.018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 27.5] [Reference Citation Analysis]
|
| 130 |
Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, Liu J, Ren P, Balakrishnan M, Cihlar T, Tseng CK, Makino S, Menachery VD, Bilello JP, Shi PY. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. bioRxiv 2020:2020. [PMID: 32607511 DOI: 10.1101/2020.06.22.165712] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 131 |
[DOI: 10.1101/2020.04.10.20061358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 132 |
El-Ghiaty MA, Shoieb SM, El-Kadi AOS. Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms. Med Hypotheses 2020;144:110033. [PMID: 32758877 DOI: 10.1016/j.mehy.2020.110033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 133 |
[DOI: 10.1101/2020.03.24.20042366] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
| 134 |
Xie M, Chen Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 2020;94:119-24. [PMID: 32247050 DOI: 10.1016/j.ijid.2020.03.071] [Cited by in Crossref: 206] [Cited by in F6Publishing: 153] [Article Influence: 103.0] [Reference Citation Analysis]
|
| 135 |
Romeo I, Mesiti F, Lupia A, Alcaro S. Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. Molecules 2021;26:632. [PMID: 33530467 DOI: 10.3390/molecules26030632] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 136 |
Aziz PY, Hadi JM, Sha AM, Aziz SB, Rahman HS, Ahmed HA, Abdulla MA, Amine Ali SM. The strategy for controlling COVID-19 in Kurdistan Regional Government (KRG)/Iraq: Identification, epidemiology, transmission, treatment, and recovery. Int J Surg Open 2020;25:41-6. [PMID: 34568609 DOI: 10.1016/j.ijso.2020.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 137 |
Pimentel J, Andersson N. Chloroquine and its derivatives in the management of COVID-19: A scoping review. Biomedica 2020;40:80-95. [PMID: 33152192 DOI: 10.7705/biomedica.5478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 138 |
El Ouarradi A, Abdeladim S, Oualim S, Filali RA, Bensahi I, Elharass M, Hafid S, Tazi H, Naitlhou A, Bouaiti EA, Moustaghfir A, Sabry M. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Electrocardiogram Variability. J Saudi Heart Assoc 2020;32:350-7. [PMID: 33299775 DOI: 10.37616/2212-5043.1088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 139 |
Agrawal M, Saraf S, Saraf S, Murty US, Kurundkar SB, Roy D, Joshi P, Sable D, Choudhary YK, Kesharwani P, Alexander A. In-line treatments and clinical initiatives to fight against COVID-19 outbreak. Respir Med 2020;:106192. [PMID: 33199136 DOI: 10.1016/j.rmed.2020.106192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 140 |
Demsie DG, Gebre AK, Yimer EM, Alema NM, Araya EM, Bantie AT, Allene MD, Gebremedhin H, Yehualaw A, Tafere C, Tadese HT, Amare B, Weldekidan E, Gebrie D. Glycopeptides as Potential Interventions for COVID-19. Biologics 2020;14:107-14. [PMID: 33116397 DOI: 10.2147/BTT.S262705] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 141 |
Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, Laksman Z, Healey JS, Krahn AD. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol 2020;36:948-51. [PMID: 32299753 DOI: 10.1016/j.cjca.2020.04.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 36.5] [Reference Citation Analysis]
|
| 142 |
[DOI: 10.1101/2020.03.29.014407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 143 |
Feng Z, Chen M, Liang T, Shen M, Chen H, Xie XQ. Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research. Brief Bioinform 2021;22:882-95. [PMID: 32715315 DOI: 10.1093/bib/bbaa155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 144 |
Yang N, Shen HM. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. Int J Biol Sci. 2020;16:1724-1731. [PMID: 32226290 DOI: 10.7150/ijbs.45498] [Cited by in Crossref: 216] [Cited by in F6Publishing: 208] [Article Influence: 108.0] [Reference Citation Analysis]
|
| 145 |
Xie D, He S, Han L, Wu L, Huang H, Tao H, Zhou P, Shi X, Bai H, Bo X. Systematic optimization of host-directed therapeutic targets and preclinical validation of repositioned antiviral drugs. Brief Bioinform 2022:bbac047. [PMID: 35238349 DOI: 10.1093/bib/bbac047] [Reference Citation Analysis]
|
| 146 |
Rahimkhoei V, Jabbari N, Nourani A, Sharifi S, Akbari A. Potential small-molecule drugs as available weapons to fight novel coronavirus (2019-nCoV): A review. Cell Biochem Funct 2021;39:4-9. [PMID: 32803762 DOI: 10.1002/cbf.3576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 147 |
Scalise M, Indiveri C. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19. SLAS DISCOVERY: Advancing the Science of Drug Discovery 2020;25:1171-3. [DOI: 10.1177/2472555220934421] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 148 |
Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, Scarlata S, Agrò FE. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288:192-206. [PMID: 32348588 DOI: 10.1111/joim.13091] [Cited by in Crossref: 375] [Cited by in F6Publishing: 309] [Article Influence: 187.5] [Reference Citation Analysis]
|
| 149 |
Hong Z, Duan X, Wu S, Yanfang Y, Wu H. Network Pharmacology Integrated Molecular Docking Reveals the Anti-COVID-19 Mechanism of Qing-Fei-Da-Yuan Granules. Natural Product Communications 2020;15:1934578X2093421. [DOI: 10.1177/1934578x20934219] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 150 |
Vanden Eynde JJ. COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes? Pharmaceuticals (Basel) 2021;14:664. [PMID: 34358090 DOI: 10.3390/ph14070664] [Reference Citation Analysis]
|
| 151 |
[DOI: 10.1101/2020.04.06.20042580] [Cited by in Crossref: 21] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 152 |
Singh AK, Singh A, Singh R, Misra A. "Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis. Diabetes Metab Syndr. 2020;14:589-596. [PMID: 32417708 DOI: 10.1016/j.dsx.2020.05.017] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 33.0] [Reference Citation Analysis]
|
| 153 |
Hosseini FS, Amanlou M. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Life Sci 2020;258:118205. [PMID: 32777300 DOI: 10.1016/j.lfs.2020.118205] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 154 |
Emrani J, Ahmed M, Jeffers-Francis L, Teleha JC, Mowa N, Newman RH, Thomas MD. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. Int J Biol Macromol 2021;193:1249-73. [PMID: 34756970 DOI: 10.1016/j.ijbiomac.2021.10.172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 155 |
Bahmani AHA, Hoorang M, Hosseini S, Eskandari M, Shayestehfard K, Shekoohi M, Hatami-Mazinani N, Afifi S, Sabzghabaee AM, Peymani P. Pharmacological and Nonpharmacological Studies on Coronavirus Disease 2019: A Mini-review of the Recent Evidence. J Res Pharm Pract 2020;9:175-80. [PMID: 33912499 DOI: 10.4103/jrpp.JRPP_20_71] [Reference Citation Analysis]
|
| 156 |
Mendoza-Pinto C, García-Carrasco M, Realpozo PM, Méndez-Martínez S. [Therapeutic options for the management of severe Covid-19: A rheumatology perspective]. Reumatol Clin (Engl Ed) 2020. [PMID: 32426002 DOI: 10.1016/j.reuma.2020.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 157 |
Biscetti F, Rando MM, Nardella E, Cecchini AL, Bruno P, Landolfi R, Flex A. Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. Int J Mol Sci 2020;21:E8141. [PMID: 33143371 DOI: 10.3390/ijms21218141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 158 |
Mubagwa K. Cardiac effects and toxicity of chloroquine: a short update. Int J Antimicrob Agents 2020;56:106057. [PMID: 32565195 DOI: 10.1016/j.ijantimicag.2020.106057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 159 |
Maciorowski D, Idrissi SZE, Gupta Y, Medernach BJ, Burns MB, Becker DP, Durvasula R, Kempaiah P. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. SLAS Discov 2020;25:1108-22. [PMID: 32942923 DOI: 10.1177/2472555220958385] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 160 |
Katulanda P, Dissanayake HA, Ranathunga I, Ratnasamy V, Wijewickrama PSA, Yogendranathan N, Gamage KKK, de Silva NL, Sumanatilleke M, Somasundaram NP, Matthews DR. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia 2020;63:1440-52. [PMID: 32405783 DOI: 10.1007/s00125-020-05164-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 27.5] [Reference Citation Analysis]
|
| 161 |
Schiavone M, Gasperetti A, Gherbesi E, Bergamaschi L, Arosio R, Mitacchione G, Viecca M, Forleo GB. Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19. Cardiac Electrophysiology Clinics 2021. [DOI: 10.1016/j.ccep.2021.10.009] [Reference Citation Analysis]
|
| 162 |
Zhan X, Dowell S, Shen Y, Lee DL. Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? Heliyon 2020;6:e04900. [PMID: 32935064 DOI: 10.1016/j.heliyon.2020.e04900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 163 |
Nittari G, Pallotta G, Amenta F, Tayebati SK. Current pharmacological treatments for SARS-COV-2: A narrative review. Eur J Pharmacol 2020;882:173328. [PMID: 32603692 DOI: 10.1016/j.ejphar.2020.173328] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 164 |
Hähnel V, Peterhoff D, Bäuerlein V, Brosig AM, Pamler I, Johnson C, Bica A, Totir M, Ossner T, Stemmer B, Toelge M, Schütz A, Niller HH, Schmidt B, Wagner R, Gessner A, Burkhard R, Offner R. Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality. PLoS One 2020;15:e0243967. [PMID: 33351831 DOI: 10.1371/journal.pone.0243967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 165 |
Zhao M, Zhang J, Li H, Luo Z, Ye J, Xu Y, Wang Z, Ye D, Liu J, Li D, Wang M, Wan J. Recent progress of antiviral therapy for coronavirus disease 2019. Eur J Pharmacol. 2021;890:173646. [PMID: 33190802 DOI: 10.1016/j.ejphar.2020.173646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 166 |
Tselios K, Skendros P. Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. Eur J Rheumatol 2020;7:S110-6. [PMID: 32432527 DOI: 10.5152/eurjrheum.2020.2064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 167 |
Cortes AA, Zuñiga JM. The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review. Diagn Microbiol Infect Dis 2020;98:115176. [PMID: 33069048 DOI: 10.1016/j.diagmicrobio.2020.115176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 168 |
Singh R, Kang A, Luo X, Jeyanathan M, Gillgrass A, Afkhami S, Xing Z. COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. FASEB J 2021;35:e21409. [PMID: 33577115 DOI: 10.1096/fj.202002662R] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 169 |
Morand A, Fabre A, Minodier P, Boutin A, Vanel N, Bosdure E, Fournier PE. COVID-19 virus and children: What do we know? Arch Pediatr 2020;27:117-8. [PMID: 32253003 DOI: 10.1016/j.arcped.2020.03.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 170 |
Russo V, Bottino R, Carbone A, Rago A, Papa AA, Golino P, Nigro G. COVID-19 and Heart: From Clinical Features to Pharmacological Implications. J Clin Med 2020;9:E1944. [PMID: 32580344 DOI: 10.3390/jcm9061944] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 171 |
Bein B, Bachmann M, Huggett S, Wegermann P. SARS-CoV-2/COVID-19: Evidence-Based Recommendations on Diagnosis and Therapy. Geburtshilfe Frauenheilkd 2020;80:491-8. [PMID: 32435065 DOI: 10.1055/a-1156-3991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 172 |
Triggle CR, Bansal D, Ding H, Islam MM, Farag EABA, Hadi HA, Sultan AA. A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Front Immunol 2021;12:631139. [PMID: 33717166 DOI: 10.3389/fimmu.2021.631139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 173 |
Iqbal P, Ata F, Rose S, Chaudhry HS, Rahil A. Should We Rely on Screening Tests for Further Management Alone in Polymerase Chain Reaction Negative COVID-19 Patients? A Case Series. Cureus 2020;12:e10555. [PMID: 33101802 DOI: 10.7759/cureus.10555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 174 |
Gök A, Kara A. Individuals' conceptions of COVID-19 pandemic through metaphor analysis. Curr Psychol 2021;:1-10. [PMID: 33776382 DOI: 10.1007/s12144-021-01506-z] [Reference Citation Analysis]
|
| 175 |
Campos DMO, Oliveira CBS, Andrade JMA, Oliveira JIN. Fighting COVID-19. Braz J Biol 2020;80:698-701. [PMID: 32555974 DOI: 10.1590/1519-6984.238155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 176 |
Chen CP, Lin YC, Chen TC, Tseng TY, Wong HL, Kuo CY, Lin WP, Huang SR, Wang WY, Liao JH, Liao CS, Hung YP, Lin TH, Chang TY, Hsiao CF, Huang YW, Chung WS, Cheng CY, Cheng SH; Taiwan HCQ Study Group. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One 2020;15:e0242763. [PMID: 33264337 DOI: 10.1371/journal.pone.0242763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 177 |
Sun H, Su X, Huang L, Mu D, Qu Y. Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. Biomolecules 2021;11:196. [PMID: 33573324 DOI: 10.3390/biom11020196] [Reference Citation Analysis]
|
| 178 |
Mehta B, Salmon J, Ibrahim S. Potential Shortages of Hydroxychloroquine for Patients with Lupus During the Coronavirus Disease 2019 Pandemic. JAMA Health Forum 2020;1:e200438. [DOI: 10.1001/jamahealthforum.2020.0438] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 179 |
Ng KK, Ng MK, Zhyvotovska A, Singh S, Shevde K. Acute Respiratory Failure Secondary to COVID-19 Viral Pneumonia Managed With Hydroxychloroquine/Azithromycin Treatment. Cureus 2020;12:e8268. [PMID: 32596085 DOI: 10.7759/cureus.8268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 180 |
Kumar V. Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. Int Rev Immunol 2021;40:5-53. [PMID: 32744465 DOI: 10.1080/08830185.2020.1800688] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 181 |
Ma L, Song K, Huang Y. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications. J Cardiothorac Vasc Anesth 2021;35:1860-5. [PMID: 32451271 DOI: 10.1053/j.jvca.2020.04.041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 182 |
Daoud I, Mesli F, Melkemi N, Ghalem S, Salah T. Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation. J Biomol Struct Dyn 2021;:1-18. [PMID: 34541995 DOI: 10.1080/07391102.2021.1973563] [Reference Citation Analysis]
|
| 183 |
Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. In Vivo. 2020;34:1597-1602. [PMID: 32503817 DOI: 10.21873/invivo.11949] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 184 |
Lotfi B, Farshid S, Dadashzadeh N, Valizadeh R, Rahimi MM. Is Coronavirus Disease 2019 (COVID-19) Associated with Renal Involvement? A Review of Century Infection. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.102899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 185 |
Shetty R, Murugeswari P, Chakrabarty K, Jayadev C, Matalia H, Ghosh A, Das D. Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Cytotherapy 2021;23:471-82. [PMID: 33257213 DOI: 10.1016/j.jcyt.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 186 |
Trindade GG, Caxito SMC, Xavier AREO, Xavier MAS, BrandÃo F. COVID-19: therapeutic approaches description and discussion. An Acad Bras Cienc 2020;92:e20200466. [PMID: 32556054 DOI: 10.1590/0001-3765202020200466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 187 |
Sivandzadeh GR, Askari H, Safarpour AR, Ejtehadi F, Raeis-Abdollahi E, Vaez Lari A, Abazari MF, Tarkesh F, Bagheri Lankarani K. COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. World J Clin Cases 2021; 9(22): 6178-6200 [PMID: 34434987 DOI: 10.12998/wjcc.v9.i22.6178] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 188 |
Francés-Monerris A, Hognon C, Miclot T, García-Iriepa C, Iriepa I, Terenzi A, Grandemange S, Barone G, Marazzi M, Monari A. Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. J Proteome Res 2020;19:4291-315. [PMID: 33119313 DOI: 10.1021/acs.jproteome.0c00779] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 189 |
Cardoso VMDO, Moreira BJ, Comparetti EJ, Sampaio I, Ferreira LMB, Lins PMP, Zucolotto V. Is Nanotechnology Helping in the Fight Against COVID-19? Front Nanotechnol 2020;2:588915. [DOI: 10.3389/fnano.2020.588915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 190 |
Annie FH, Sirbu C, Frazier KR, Broce M, Lucas BD Jr. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. Pharmacotherapy 2020;40:1072-81. [PMID: 33044019 DOI: 10.1002/phar.2467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 191 |
Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, Atif SM, Hariprasad G, Hasan GM, Hassan MI. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis 2020;1866:165878. [PMID: 32544429 DOI: 10.1016/j.bbadis.2020.165878] [Cited by in Crossref: 211] [Cited by in F6Publishing: 186] [Article Influence: 105.5] [Reference Citation Analysis]
|
| 192 |
Li CX, Noreen S, Zhang LX, Saeed M, Wu PF, Ijaz M, Dai DF, Maqbool I, Madni A, Akram F, Naveed M, Li JH. A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. Biomed Pharmacother 2021;146:112550. [PMID: 34959116 DOI: 10.1016/j.biopha.2021.112550] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 193 |
Zhang Z, Wang S, Tu X, Peng X, Huang Y, Wang L, Ju W, Rao J, Li X, Zhu D, Sun H, Chen H. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. J Med Virol 2020;92:2631-6. [PMID: 32501538 DOI: 10.1002/jmv.26141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 194 |
Zou H, Yang Y, Dai H, Xiong Y, Wang JQ, Lin L, Chen ZS. Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. Front Pharmacol 2021;12:732403. [PMID: 34880750 DOI: 10.3389/fphar.2021.732403] [Reference Citation Analysis]
|
| 195 |
Antoniello A, Brophy A, Opsha Y. Evaluation of Hospitalized Patient Outcomes in COVID-19 Infection for Continued versus Discontinued Use of Preadmission Antiplatelet Regimen. J Pharm Pract 2021;:8971900211053294. [PMID: 34693824 DOI: 10.1177/08971900211053294] [Reference Citation Analysis]
|
| 196 |
Senger MR, Evangelista TCS, Dantas RF, Santana MVDS, Gonçalves LCS, de Souza Neto LR, Ferreira SB, Silva-Junior FP. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Mem Inst Oswaldo Cruz 2020;115:e200254. [PMID: 33027420 DOI: 10.1590/0074-02760200254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 197 |
[DOI: 10.1101/2020.05.04.20089904] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 198 |
Fernandez-Gutierrez B, Leon L, Madrid A, Rodriguez-Rodriguez L, Freites D, Font J, Mucientes A, Culebras E, Colome JI, Jover JA, Abasolo L. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis 2021;13:1759720X20962692. [PMID: 33613703 DOI: 10.1177/1759720X20962692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 199 |
Gould S, Norris SL. Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19. Cochrane Database Syst Rev 2021;3:ED000151. [PMID: 33765340 DOI: 10.1002/14651858.ED000151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 200 |
Srinivasan K, Pandey AK, Livingston A, Venkatesh S. Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target? Mol Biomed 2021;2:38. [PMID: 34841263 DOI: 10.1186/s43556-021-00060-1] [Reference Citation Analysis]
|
| 201 |
Valencia DN. Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. Cureus 2020;12:e7386. [PMID: 32337113 DOI: 10.7759/cureus.7386] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 202 |
Gopinathannair R, Merchant FM, Lakkireddy DR, Etheridge SP, Feigofsky S, Han JK, Kabra R, Natale A, Poe S, Saha SA, Russo AM. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol 2020;59:329-36. [PMID: 32494896 DOI: 10.1007/s10840-020-00789-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 20.5] [Reference Citation Analysis]
|
| 203 |
Uma Reddy B, Routhu NK, Kumar A. Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2. Microbial Pathogenesis 2022. [DOI: 10.1016/j.micpath.2022.105512] [Reference Citation Analysis]
|
| 204 |
Farzana M, Shahriar S, Jeba FR, Tabassum T, Araf Y, Ullah MA, Tasnim J, Chakraborty A, Naima TA, Marma KKS, Rahaman TI, Hosen MJ. Functional food: complementary to fight against COVID-19. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00217-z] [Reference Citation Analysis]
|
| 205 |
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020;14:241-6. [PMID: 32247211 DOI: 10.1016/j.dsx.2020.03.011] [Cited by in Crossref: 208] [Cited by in F6Publishing: 183] [Article Influence: 104.0] [Reference Citation Analysis]
|
| 206 |
Liu JB, Arockiaraj M, Arulperumjothi M, Prabhu S. Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19. Int J Quantum Chem 2021;:e26617. [PMID: 33785968 DOI: 10.1002/qua.26617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 207 |
Mo L, Zheng P. [Chloroquine phosphate: therapeutic drug for COVID-19]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:586-94. [PMID: 32895128 DOI: 10.12122/j.issn.1673-4254.2020.04.22] [Reference Citation Analysis]
|
| 208 |
K Konstantinidou S, P Papanastasiou I. Repurposing current therapeutic regimens against SARS-CoV-2 (Review). Exp Ther Med 2020;20:1845-55. [PMID: 32782493 DOI: 10.3892/etm.2020.8905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 209 |
Romano S, Galante H, Figueira D, Mendes Z, Rodrigues AT. Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies. Res Social Adm Pharm 2021;17:1876-81. [PMID: 32482587 DOI: 10.1016/j.sapharm.2020.05.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 210 |
Ali S, Khan AT. An environmentally benign regioselective synthesis of 2-benzyl-4-arylquinoline derivatives using aryl amines, styrene oxides and aryl acetylenes. Org Biomol Chem 2021;19:8772-82. [PMID: 34591056 DOI: 10.1039/d1ob01699g] [Reference Citation Analysis]
|
| 211 |
Ismaila MS, Bande F, Ishaka A, Sani AA, Georges K. Therapeutic options for COVID-19: a quick review. J Chemother. 2021;33:67-84. [PMID: 33427110 DOI: 10.1080/1120009x.2020.1868237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 212 |
Braz HLB, Silveira JAM, Marinho AD, de Moraes MEA, Moraes Filho MO, Monteiro HSA, Jorge RJB. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Int J Antimicrob Agents 2020;56:106119. [PMID: 32738306 DOI: 10.1016/j.ijantimicag.2020.106119] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 213 |
Srivastava K, Singh MK. Drug repurposing in COVID-19: A review with past, present and future. Metabol Open 2021;12:100121. [PMID: 34462734 DOI: 10.1016/j.metop.2021.100121] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 214 |
Favalli EG, Agape E, Caporali R. Dr. Favalli, et al reply. J Rheumatol 2020;47:1592. [PMID: 32482654 DOI: 10.3899/jrheum.200723] [Reference Citation Analysis]
|
| 215 |
Sinha K, Chaudhury SS, Sharma P, Ruidas B. Covid-19 rhapsody: Rage towards advanced diagnostics and therapeutic strategy. J Pharm Anal 2021. [PMID: 34178413 DOI: 10.1016/j.jpha.2021.06.004] [Reference Citation Analysis]
|
| 216 |
Fagan N, Meah N, York K, Bokhari L, Fletcher G, Chen G, Tobin DJ, Messenger A, Irvine AD, Sinclair R, Wall D. Shedding light on therapeutics in alopecia and their relevance to COVID-19. Clin Dermatol 2021;39:76-83. [PMID: 33972056 DOI: 10.1016/j.clindermatol.2020.12.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 217 |
Fernández-Lázaro D, González-Bernal JJ, Sánchez-Serrano N, Navascués LJ, Ascaso-Del-Río A, Mielgo-Ayuso J. Physical Exercise as a Multimodal Tool for COVID-19: Could It Be Used as a Preventive Strategy? Int J Environ Res Public Health 2020;17:E8496. [PMID: 33212762 DOI: 10.3390/ijerph17228496] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 218 |
Gasmi A, Peana M, Noor S, Lysiuk R, Menzel A, Gasmi Benahmed A, Bjørklund G. Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. Appl Microbiol Biotechnol 2021;105:1333-43. [PMID: 33515285 DOI: 10.1007/s00253-021-11094-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 219 |
Rando HM, Wellhausen N, Ghosh S, Lee AJ, Dattoli AA, Hu F, Byrd JB, Rafizadeh DN, Lordan R, Qi Y, Sun Y, Brueffer C, Field JM, Ben Guebila M, Jadavji NM, Skelly AN, Ramsundar B, Wang J, Goel RR, Park Y, Boca SM, Gitter A, Greene CS; COVID-19 Review Consortium Vikas Bansal, John P. Barton, Simina M. Boca, Joel D. Boerckel, Christian Brueffer, James Brian Byrd, Stephen Capone, Shikta Das, Anna Ada Dattoli, John J. Dziak, Jeffrey M. Field, Soumita Ghosh, Anthony Gitter, Rishi Raj Goel, Casey S. Greene, Marouen Ben Guebila, Daniel S. Himmelstein, Fengling Hu, Nafisa M. Jadavji, Jeremy P. Kamil, Sergey Knyazev, Likhitha Kolla, Alexandra J. Lee, Ronan Lordan, Tiago Lubiana, Temitayo Lukan, Adam L. MacLean, David Mai, Serghei Mangul, David Manheim, Lucy D’Agostino McGowan, Amruta Naik, YoSon Park, Dimitri Perrin, Yanjun Qi, Diane N. Rafizadeh, Bharath Ramsundar, Halie M. Rando, Sandipan Ray, Michael P. Robson, Vincent Rubinetti, Elizabeth Sell, Lamonica Shinholster, Ashwin N. Skelly, Yuchen Sun, Yusha Sun, Gregory L. Szeto, Ryan Velazquez, Jinhui Wang, Nils Wellhausen. Identification and Development of Therapeutics for COVID-19. mSystems 2021;:e0023321. [PMID: 34726496 DOI: 10.1128/mSystems.00233-21] [Reference Citation Analysis]
|
| 220 |
Beeraka NM, Sadhu SP, Madhunapantula SV, Rao Pragada R, Svistunov AA, Nikolenko VN, Mikhaleva LM, Aliev G. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status. Front Immunol 2020;11:552925. [PMID: 33072093 DOI: 10.3389/fimmu.2020.552925] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 221 |
Gebru AA, Birhanu T, Wendimu E, Ayalew AF, Mulat S, Abasimel HZ, Kazemi A, Tadesse BA, Gebru BA, Deriba BS, Zeleke NS, Girma AG, Munkhbat B, Yusuf QK, Luke AO, Hailu D. Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19. Hum Antibodies 2021;29:129-37. [PMID: 32865184 DOI: 10.3233/HAB-200422] [Reference Citation Analysis]
|
| 222 |
Gour A, Manhas D, Bag S, Gorain B, Nandi U. Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2. Phytother Res 2021;35:4258-83. [PMID: 33786876 DOI: 10.1002/ptr.7092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 223 |
Halder P, Pal U, Paladhi P, Dutta S, Paul P, Pal S, Das D, Ganguly A, IshitaDutta, SayarneelMandal, Ray A, Ghosh S. Evaluation of potency of the selected bioactive molecules from Indian medicinal plants with MPro of SARS-CoV-2 through in silico analysis. J Ayurveda Integr Med 2021. [PMID: 34054246 DOI: 10.1016/j.jaim.2021.05.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 224 |
Ma Z, Yang KY, Huang Y, Lui KO. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. J Mol Cell Cardiol 2021;164:69-82. [PMID: 34838588 DOI: 10.1016/j.yjmcc.2021.11.010] [Reference Citation Analysis]
|
| 225 |
Li L, Wang X, Wang R, Hu Y, Jiang S, Lu X. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Des Devel Ther. 2020;14:3001-3013. [PMID: 32801640 DOI: 10.2147/dddt.s259058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 226 |
Mendoza-Pinto C, García-Carrasco M, Munguía Realpozo P, Méndez-Martínez S. Therapeutic options for the management of severe COVID-19: A rheumatology perspective. Reumatol Clin (Engl Ed) 2021;17:431-6. [PMID: 34625144 DOI: 10.1016/j.reumae.2020.05.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 227 |
Mahmud S, Biswas S, Kumar Paul G, Mita MA, Afrose S, Robiul Hasan M, Sharmin Sultana Shimu M, Uddin MAR, Salah Uddin M, Zaman S, Kaderi Kibria KM, Arif Khan M, Bin Emran T, Abu Saleh M. Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study. Arab J Chem 2021;14:103315. [PMID: 34909064 DOI: 10.1016/j.arabjc.2021.103315] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 228 |
Fantini J, Chahinian H, Yahi N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Int J Antimicrob Agents 2020;56:106020. [PMID: 32405156 DOI: 10.1016/j.ijantimicag.2020.106020] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
|
| 229 |
Demircan S, Demirçivi Bör E. Knowledge, perception, and protective measures of Turkish pregnant women towards COVID-19 pandemic and their effects on anxiety levels. J Obstet Gynaecol 2021;:1-5. [PMID: 34927534 DOI: 10.1080/01443615.2021.1990232] [Reference Citation Analysis]
|
| 230 |
Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. Int J Mol Sci 2020;21:E3330. [PMID: 32397174 DOI: 10.3390/ijms21093330] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 22.5] [Reference Citation Analysis]
|
| 231 |
Chaturvedi M, Nagre K, Yadav JP. In silico approach for identification of natural compounds as potential COVID 19 main protease (Mpro) inhibitors. Virusdisease 2021;:1-5. [PMID: 34179304 DOI: 10.1007/s13337-021-00701-7] [Reference Citation Analysis]
|
| 232 |
He F, Luo Q, Lei M, Fan L, Shao X, Hu K, Qin S, Yu N, Cao J, Yang L. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. Clin Rheumatol 2020;39:2803-10. [PMID: 32725351 DOI: 10.1007/s10067-020-05230-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 233 |
Kandimalla R, John A, Abburi C, Vallamkondu J, Reddy PH. Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. Mol Neurobiol 2020;57:4106-16. [PMID: 32671688 DOI: 10.1007/s12035-020-02022-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 234 |
Liu Q, Bi G, Chen G, Guo X, Tu S, Tong X, Xu M, Liu M, Wang B, Jiang H, Wang J, Li H, Wang K, Liu D, Song C. Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. Front Pharmacol 2020;11:602880. [PMID: 33519466 DOI: 10.3389/fphar.2020.602880] [Reference Citation Analysis]
|
| 235 |
Nasiri R, Akbarpour S, Zali AR, Khodakarami N, Boochani MH, Noory AR, Soori H. Spatio-temporal analysis of COVID-19 incidence rate using GIS: a case study-Tehran metropolitan, Iran. GeoJournal 2021;:1-15. [PMID: 33994652 DOI: 10.1007/s10708-021-10438-x] [Reference Citation Analysis]
|
| 236 |
Bibi N, Gul S, Ali J, Kamal MA. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. Eur J Pharmacol 2020;885:173496. [PMID: 32841640 DOI: 10.1016/j.ejphar.2020.173496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 237 |
Mitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A, Ballana E, Alemany A, Riera-Martí N, Pérez CA, Suñer C, Laporte P, Admella P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Casabona J, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, Muntada E, Nadal N, Narejos S, Gil-Ortega AN, Prat N, Puig J, Quiñones C, Reyes-Ureña J, Ramírez-Viaplana F, Ruiz L, Riveira-Muñoz E, Sierra A, Velasco C, Vivanco-Hidalgo RM, Sentís A, G-Beiras C, Clotet B, Vall-Mayans M; BCN PEP-CoV-2 RESEARCH GROUP. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. Clin Infect Dis 2020:ciaa1009. [PMID: 32674126 DOI: 10.1093/cid/ciaa1009] [Cited by in Crossref: 77] [Cited by in F6Publishing: 107] [Article Influence: 38.5] [Reference Citation Analysis]
|
| 238 |
Sogut O, Can MM, Guven R, Kaplan O, Ergenc H, Umit TB, Demir O, Kaya M, Akdemir T, Cakmak S. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study. Am J Emerg Med 2021;40:41-6. [PMID: 33348222 DOI: 10.1016/j.ajem.2020.12.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 239 |
Duan Y, Yao Y, Kumar SA, Zhu HL, Chang J. Current and future therapeutical approaches for COVID-19. Drug Discov Today 2020;25:1545-52. [PMID: 32574697 DOI: 10.1016/j.drudis.2020.06.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 240 |
Abrams-Downey A, Saabiye J, Vidaurrazaga M. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. Eur Urol Focus 2020;6:1028-31. [PMID: 32563675 DOI: 10.1016/j.euf.2020.05.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 241 |
Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55:105960. [PMID: 32251731 DOI: 10.1016/j.ijantimicag.2020.105960] [Cited by in Crossref: 263] [Cited by in F6Publishing: 229] [Article Influence: 131.5] [Reference Citation Analysis]
|
| 242 |
Moris D, Kesseli SJ, Barbas AS. Kidney transplant recipients infected by COVID-19: Review of the initial published experience. Transpl Infect Dis 2020;22:e13426. [PMID: 32702150 DOI: 10.1111/tid.13426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 243 |
Duran N, Polat MF, Aktas DA, Alagoz MA, Ay E, Cimen F, Tek E, Anil B, Burmaoglu S, Algul O. New chalcone derivatives as effective against SARS-CoV-2 agent. Int J Clin Pract 2021;75:e14846. [PMID: 34519118 DOI: 10.1111/ijcp.14846] [Reference Citation Analysis]
|
| 244 |
Yao X, Yan X, Wang X, Cai T, Zhang S, Cui C, Wang X, Hou Z, Liu Q, Li H, Lin J, Xiong Z, Liu D. Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. Eur J Clin Pharmacol 2021;77:583-93. [PMID: 33188451 DOI: 10.1007/s00228-020-03032-6] [Reference Citation Analysis]
|
| 245 |
Danladi J, Sabir H. Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis. J Neuroimmunol 2021;358:577632. [PMID: 34186336 DOI: 10.1016/j.jneuroim.2021.577632] [Reference Citation Analysis]
|
| 246 |
Chivese T, Musa OAH, Hindy G, Al-Wattary N, Badran S, Soliman N, Aboughalia ATM, Matizanadzo JT, Emara MM, Thalib L, Doi SAR. Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. Travel Med Infect Dis 2021;43:102135. [PMID: 34265436 DOI: 10.1016/j.tmaid.2021.102135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 247 |
Saghir SAM, AlGabri NA, Alagawany MM, Attia YA, Alyileili SR, Elnesr SS, Shafi ME, Al-Shargi OYA, Al-Balagi N, Alwajeeh AS, Alsalahi OSA, Patra AK, Khafaga AF, Negida A, Noreldin A, Al-Amarat W, Almaiman AA, El-Tarabily KA, Abd El-Hack ME. Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. Ther Clin Risk Manag 2021;17:371-87. [PMID: 33953559 DOI: 10.2147/TCRM.S301817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 248 |
Stojkovic-Filipovic J, Bosic M. Treatment of COVID 19-Repurposing drugs commonly used in dermatology. Dermatol Ther 2020;33:e13829. [PMID: 32542964 DOI: 10.1111/dth.13829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 249 |
Pham PV, Vu NB. Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations. World J Stem Cells 2020; 12(8): 721-730 [PMID: 32952854 DOI: 10.4252/wjsc.v12.i8.721] [Reference Citation Analysis]
|
| 250 |
Mitra P. Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection. Am J Physiol Cell Physiol 2020;319:C500-9. [PMID: 32687406 DOI: 10.1152/ajpcell.00260.2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 251 |
Dhampalwar S, Saigal S, Soin AS. Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. J Clin Exp Hepatol 2020;10:599-609. [PMID: 32837097 DOI: 10.1016/j.jceh.2020.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 252 |
Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. Clin Transl Sci 2020;13:642-5. [PMID: 32268005 DOI: 10.1111/cts.12797] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 253 |
McGrowder DA, Miller F, Anderson Cross M, Anderson-Jackson L, Bryan S, Dilworth L. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. Diseases 2021;9:50. [PMID: 34287285 DOI: 10.3390/diseases9030050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 254 |
Spuch C, López-garcía M, Rivera-baltanás T, Cabrera-alvargonzález JJ, Gadh S, Rodrigues-amorim D, Álvarez-estévez T, Mora A, Iglesias-martínez-almeida M, Freiría-martínez L, Pérez-rodríguez M, Pérez-gonzález A, López-domínguez A, Longueira-suarez MR, Sousa-domínguez A, Araújo-ameijeiras A, Mosquera-rodríguez D, Crespo M, Vila-fernández D, Regueiro B, Olivares JM. Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. Front Pharmacol 2022;13:850583. [DOI: 10.3389/fphar.2022.850583] [Reference Citation Analysis]
|
| 255 |
Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, Pullen MF, Rajasingham R, McDonald EG, Lee TC, Schwartz IS, Kelly LE, Lother SA, Mitjà O, Letang E, Abassi M, Boulware DR. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020;7:ofaa130. [PMID: 32363212 DOI: 10.1093/ofid/ofaa130] [Cited by in Crossref: 98] [Cited by in F6Publishing: 84] [Article Influence: 49.0] [Reference Citation Analysis]
|
| 256 |
El Baz S, Imziln B. Coronavirus Disease 2019 (COVID‐19): Morocco Interrupting the Transmission by Ethics, Logistics, and Therapeutics Efforts. J Clin Exp Invest 2020;11:em00743. [DOI: 10.5799/jcei/8214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 257 |
Nitulescu GM, Paunescu H, Moschos SA, Petrakis D, Nitulescu G, Ion GND, Spandidos DA, Nikolouzakis TK, Drakoulis N, Tsatsakis A. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review). Int J Mol Med 2020;46:467-88. [PMID: 32468014 DOI: 10.3892/ijmm.2020.4608] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 23.0] [Reference Citation Analysis]
|
| 258 |
Passarelli PC, Rella E, Manicone PF, Garcia-Godoy F, D'Addona A. The impact of the COVID-19 infection in dentistry. Exp Biol Med (Maywood) 2020;245:940-4. [PMID: 32436748 DOI: 10.1177/1535370220928905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 259 |
Shao H, Ghaly HSA, Varamini P. Coronavirus Disease 2019: An Overview of the Complications and Management. INNOSC Theranostics and Pharmacological Sciences. [DOI: 10.36922/itps.v4i1.1037] [Reference Citation Analysis]
|
| 260 |
Forns X, Navasa M. Liver transplant immunosuppression during the covid-19 pandemic. Gastroenterol Hepatol 2020;43:457-63. [PMID: 32646657 DOI: 10.1016/j.gastrohep.2020.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 261 |
RECOVERY Collaborative Group. , Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383:2030-2040. [PMID: 33031652 DOI: 10.1056/nejmoa2022926] [Cited by in Crossref: 352] [Cited by in F6Publishing: 237] [Article Influence: 176.0] [Reference Citation Analysis]
|
| 262 |
Sun J, Deng X, Chen X, Huang J, Huang S, Li Y, Feng J, Liu J, He G. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther. 2020;108:791-797. [PMID: 32324898 DOI: 10.1002/cpt.1866] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 263 |
Scialo F, Vitale M, Daniele A, Nigro E, Perrotta F, Gelzo M, Iadevaia C, Cerqua FS, Costigliola A, Allocca V, Amato F, Pastore L, Castaldo G, Bianco A. SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. Biomedicines 2021;9:611. [PMID: 34072088 DOI: 10.3390/biomedicines9060611] [Reference Citation Analysis]
|
| 264 |
Tungadi R, Tuloli TS, Abdulkadir W, Thomas N, Madania M, Hasan AM, Sapiun Z. COVID-19: Clinical Characteristics and Molecular Levels of Candidate Compounds of Prospective Herbal and Modern Drugs in Indonesia. Pharm Sci 2020;26:S12-23. [DOI: 10.34172/ps.2020.50] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 265 |
Erdem HA, Korkma PE, Çağlayan D, Işıkgöz Taşbakan M, Yamazhan T, Taşbakan MS, Sayıner A, Gökengin D. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. Turk J Med Sci 2021;51:912-20. [PMID: 33237663 DOI: 10.3906/sag-2008-33] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 266 |
Song W, Muste JC, Greenlee TE, Singh RP. Chloroquine and Hydroxychloroquine Toxicity. AJOCT 2020;2:8. [DOI: 10.25259/ajoct_2_2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 267 |
Addeo A, Friedlaender A. Cancer and COVID-19: Unmasking their ties. Cancer Treat Rev 2020;88:102041. [PMID: 32516704 DOI: 10.1016/j.ctrv.2020.102041] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 268 |
Wang Z, Zhao YP. [Influence of COVID-19 on the occurrence and treatment of hemolytic diseases]. Zhonghua Xue Ye Xue Za Zhi 2020;41:878-80. [PMID: 33190454 DOI: 10.3760/cma.j.issn.0253-2727.2020.10.021] [Reference Citation Analysis]
|
| 269 |
Sarker MT, Hasan AQF, Rafi MO, Hossain MJ, El-mageed HRA, Elsapagh RM, Capasso R, Emran TB. A Comprehensive Overview of the Newly Emerged COVID-19 Pandemic: Features, Origin, Genomics, Epidemiology, Treatment, and Prevention. Biologics 2021;1:357-83. [DOI: 10.3390/biologics1030021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 270 |
Davoodi L, Abedi SM, Salehifar E, Alizadeh-Navaei R, Rouhanizadeh H, Khorasani G, Hosseinimehr SJ. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. Int J Clin Pract 2020;74:e13600. [PMID: 32603531 DOI: 10.1111/ijcp.13600] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 271 |
Luo J, Zhu X, Jian J, Chen X, Yin K. Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. Acta Biochim Biophys Sin (Shanghai) 2021;53:273-82. [PMID: 33428706 DOI: 10.1093/abbs/gmaa176] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 272 |
Sorice M, Misasi R, Riitano G, Manganelli V, Martellucci S, Longo A, Garofalo T, Mattei V. Targeting Lipid Rafts as a Strategy Against Coronavirus. Front Cell Dev Biol 2020;8:618296. [PMID: 33614627 DOI: 10.3389/fcell.2020.618296] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 273 |
Halstead SB. An Urgent Need for "Common Cold Units" to Study COVID-19. Am J Trop Med Hyg 2020;102:1152-3. [PMID: 32274988 DOI: 10.4269/ajtmh.20-0246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 274 |
Shamim S, Khan M, Kharaba ZJ, Ijaz M, Murtaza G. Potential strategies for combating COVID-19. Arch Virol 2020;165:2419-38. [PMID: 32778950 DOI: 10.1007/s00705-020-04768-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 275 |
Majid S, Khan MS, Rashid S, Niyaz A, Farooq R, Bhat SA, Wani HA, Qureshi W. COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development. Curr Clin Microbiol Rep 2021;:1-15. [PMID: 33614398 DOI: 10.1007/s40588-021-00157-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 276 |
Kaur K, Kaushal S, Kaushal IG. Therapeutic status of hydroxychloroquine in COVID-19: A review. J Anaesthesiol Clin Pharmacol 2020;36:S160-5. [PMID: 33100674 DOI: 10.4103/joacp.JOACP_313_20] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 277 |
Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46:854-87. [PMID: 32222812 DOI: 10.1007/s00134-020-06022-5] [Cited by in Crossref: 670] [Cited by in F6Publishing: 687] [Article Influence: 335.0] [Reference Citation Analysis]
|
| 278 |
Claude-Rosny E. COVID-19 therapy and prevention. Discoveries (Craiova) 2020;8:e113. [PMID: 33094148 DOI: 10.15190/d.2020.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 279 |
Li G, Yang F, He X, Liu Z, Pi J, Zhu Y, Ke X, Liu S, Ou M, Guo H, Zhang Z, Zeng G, Zhang G. Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients. Microbes Infect 2020;22:119-26. [PMID: 31678658 DOI: 10.1016/j.micinf.2019.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 280 |
Dutta D, Sharma M, Sharma R. Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice. Eur Endocrinol 2020;16:109-12. [PMID: 33117441 DOI: 10.17925/EE.2020.16.2.109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 281 |
Ardura M, Hartley D, Dandoy C, Lehmann L, Jaglowski S, Auletta JJ; Transplant-Associated Learning Network Team (TALNT). Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. Biol Blood Marrow Transplant 2020;26:e147-60. [PMID: 32339662 DOI: 10.1016/j.bbmt.2020.04.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 282 |
Licciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatr Rheumatol Online J 2020;18:35. [PMID: 32321540 DOI: 10.1186/s12969-020-00422-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 283 |
Mansueto G, Niola M, Napoli C. Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases? Pathol Res Pract 2020;216:153086. [PMID: 32825954 DOI: 10.1016/j.prp.2020.153086] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 284 |
Fteiha B, Karameh H, Kurd R, Ziff-Werman B, Feldman I, Bnaya A, Einav S, Orlev A, Ben-Chetrit E. QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study. Int J Clin Pract 2021;75:e13767. [PMID: 33063447 DOI: 10.1111/ijcp.13767] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 285 |
Saleem H, Rahman J, Aslam N, Murtazaliev S, Khan S. Coronavirus Disease 2019 (COVID-19) in Children: Vulnerable or Spared? A Systematic Review. Cureus 2020;12:e8207. [PMID: 32577325 DOI: 10.7759/cureus.8207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 286 |
Nippes RP, Macruz PD, da Silva GN, Neves Olsen Scaliante MH. A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment. Process Saf Environ Prot 2021;152:568-82. [PMID: 34226801 DOI: 10.1016/j.psep.2021.06.040] [Reference Citation Analysis]
|
| 287 |
Lotfy SM, Abbas A, Shouman W. Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study. Turk Thorac J 2021;22:62-6. [PMID: 33646106 DOI: 10.5152/TurkThoracJ.2021.20180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 288 |
Ullah W, M Abdullah H, Roomi S, Sattar Y, Almas T, Narayana Gowda S, Saeed R, Mukhtar M, Ahmad A, Oliver T, Alraies MC, Haas DC, Fischman DL. Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. J Clin Med Res 2020;12:483-91. [PMID: 32849936 DOI: 10.14740/jocmr4233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 289 |
Xiu S, Dick A, Ju H, Mirzaie S, Abdi F, Cocklin S, Zhan P, Liu X. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. J Med Chem 2020;63:12256-74. [PMID: 32539378 DOI: 10.1021/acs.jmedchem.0c00502] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 29.5] [Reference Citation Analysis]
|
| 290 |
Rastogi M, Pandey N, Shukla A, Singh SK. SARS coronavirus 2: from genome to infectome. Respir Res. 2020;21:318. [PMID: 33261606 DOI: 10.1186/s12931-020-01581-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 291 |
Scherrmann JM. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. AAPS J 2020;22:86. [PMID: 32533263 DOI: 10.1208/s12248-020-00465-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 292 |
Singh S, Prakash C, Ramakrishna S. Three-dimensional printing in the fight against novel virus COVID-19: Technology helping society during an infectious disease pandemic. Technol Soc 2020;62:101305. [PMID: 32834232 DOI: 10.1016/j.techsoc.2020.101305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 293 |
Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, Tanzifi A, Faramarzi F, Negarandeh R, Safdari M, Khataminia M, Rezai Ghaleno H, Habtemariam S, Khoshi A. Pharmacological treatments of COVID-19. Pharmacol Rep 2020;72:1446-78. [PMID: 32816200 DOI: 10.1007/s43440-020-00152-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 294 |
Hosseini NF, Dalirfardouei R, Aliramaei MR, Najafi R. Stem cells or their exosomes: which is preferred in COVID-19 treatment? Biotechnol Lett. [DOI: 10.1007/s10529-021-03209-8] [Reference Citation Analysis]
|
| 295 |
Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. J Allergy Clin Immunol 2020;146:285-99. [PMID: 32624257 DOI: 10.1016/j.jaci.2020.05.033] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 296 |
Gnegel G, Hauk C, Neci R, Mutombo G, Nyaah F, Wistuba D, Häfele-Abah C, Heide L. Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic. Am J Trop Med Hyg 2020;103:73-6. [PMID: 32400349 DOI: 10.4269/ajtmh.20-0363] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 297 |
Fan S, Xiao D, Wang Y, Liu L, Zhou X, Zhong W. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. Future Med Chem 2020;12:1565-78. [PMID: 32638628 DOI: 10.4155/fmc-2020-0158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 298 |
Prasad K, Khatoon F, Rashid S, Ali N, AlAsmari AF, Ahmed MZ, Alqahtani AS, Alqahtani MS, Kumar V. Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective. Int J Biol Macromol 2020;163:1-8. [PMID: 32599245 DOI: 10.1016/j.ijbiomac.2020.06.228] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 299 |
Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. Infect Genet Evol 2020;83:104327. [PMID: 32320825 DOI: 10.1016/j.meegid.2020.104327] [Cited by in Crossref: 128] [Cited by in F6Publishing: 97] [Article Influence: 64.0] [Reference Citation Analysis]
|
| 300 |
Fecchi K, Anticoli S, Peruzzu D, Iessi E, Gagliardi MC, Matarrese P, Ruggieri A. Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets. Front Microbiol 2020;11:1821. [PMID: 32849425 DOI: 10.3389/fmicb.2020.01821] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 301 |
Barzkar F, Ranjbar M, Sioofy-Khojine AB, Khajehazad M, Vesal Azad R, Moradi Y, Baradaran HR. Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies. Med J Islam Repub Iran 2020;34:171. [PMID: 33816370 DOI: 10.47176/mjiri.34.171] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 302 |
Tezer H, Bedir Demirdağ T. Novel coronavirus disease (COVID-19) in children. Turk J Med Sci 2020;50:592-603. [PMID: 32304191 DOI: 10.3906/sag-2004-174] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 303 |
Fongnzossie Fedoung E, Biwole AB, Nyangono Biyegue CF, Ngansop Tounkam M, Akono Ntonga P, Nguiamba VP, Essono DM, Forbi Funwi P, Tonga C, Nguenang GM, Kemeuze V, Sonwa DJ, Tsabang N, Bouelet IS, Tize Z, Boum AT, Momo Solefack MC, Betti JL, Nouga Bissoue A, Lehman LG, Mapongmetsem PM, Nneme Nneme L, Ngono Ngane RA, Ngogang Yonkeu J. A review of Cameroonian medicinal plants with potentials for the management of the COVID-19 pandemic. ADV TRADIT MED (ADTM). [DOI: 10.1007/s13596-021-00567-6] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 304 |
Randhawa PK, Scanlon K, Rappaport J, Gupta MK. Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. Front Physiol 2020;11:611275. [PMID: 33329064 DOI: 10.3389/fphys.2020.611275] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 305 |
Krueger J, Santinon F, Kazanova A, Issa ME, Larrivee B, Kremer R, Milhalcioiu C, Rudd CE. Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. PLoS One 2021;16:e0251731. [PMID: 34181666 DOI: 10.1371/journal.pone.0251731] [Reference Citation Analysis]
|
| 306 |
Al-Moubarak E, Sharifi M, Hancox JC. In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget. Front Cardiovasc Med 2021;8:645172. [PMID: 34017865 DOI: 10.3389/fcvm.2021.645172] [Reference Citation Analysis]
|
| 307 |
Manoj A, Bhuyan M, Raj Banik S, Ravi Sankar M. 3D printing of nasopharyngeal swabs for COVID-19 diagnose: Past and current trends. Mater Today Proc 2021;44:1361-8. [PMID: 33262931 DOI: 10.1016/j.matpr.2020.11.505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 308 |
Zhuo LS, Wang MS, Yang JF, Xu HC, Huang W, Shang LQ, Yang GF. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Top Curr Chem (Cham) 2021;379:23. [PMID: 33886017 DOI: 10.1007/s41061-021-00335-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 309 |
Owis AI, El-hawary MS, El Amir D, Aly OM, Abdelmohsen UR, Kamel MS. Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease. RSC Adv 2020;10:19570-5. [DOI: 10.1039/d0ra03582c] [Cited by in Crossref: 43] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 310 |
Yarmohammadi A, Yarmohammadi M, Fakhri S, Khan H. Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. Eur J Pharmacol 2021;890:173620. [PMID: 33038418 DOI: 10.1016/j.ejphar.2020.173620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 311 |
Dousa KM, Malavade SS, Furin J, Gripshover B, Hatszegi M, Hojat L, Saade E, Salata RA. SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis. IDCases 2020;20:e00778. [PMID: 32341910 DOI: 10.1016/j.idcr.2020.e00778] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 312 |
SoleimanvandiAzar N, Irandoost SF, Ahmadi S, Xosravi T, Ranjbar H, Mansourian M, Yoosefi Lebni J. Explaining the reasons for not maintaining the health guidelines to prevent COVID-19 in high-risk jobs: a qualitative study in Iran. BMC Public Health 2021;21:848. [PMID: 33941149 DOI: 10.1186/s12889-021-10889-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 313 |
Das S, Ramachandran AK, Birangal SR, Akbar S, Ahmed B, Joseph A. The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Med Drug Discov 2021;10:100085. [PMID: 33846702 DOI: 10.1016/j.medidd.2021.100085] [Reference Citation Analysis]
|
| 314 |
Bhattacharjee A, Saha M, Halder A, Debnath A, Mukherjee O. Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19. Curr Microbiol 2021;78:435-48. [PMID: 33392670 DOI: 10.1007/s00284-020-02310-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 315 |
Kanjanasirirat P, Suksatu A, Manopwisedjaroen S, Munyoo B, Tuchinda P, Jearawuttanakul K, Seemakhan S, Charoensutthivarakul S, Wongtrakoongate P, Rangkasenee N, Pitiporn S, Waranuch N, Chabang N, Khemawoot P, Sa-Ngiamsuntorn K, Pewkliang Y, Thongsri P, Chutipongtanate S, Hongeng S, Borwornpinyo S, Thitithanyanont A. High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci Rep 2020;10:19963. [PMID: 33203926 DOI: 10.1038/s41598-020-77003-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 316 |
Tleyjeh IM, Kashour Z, AlDosary O, Riaz M, Tlayjeh H, Garbati MA, Tleyjeh R, Al-Mallah MH, Sohail MR, Gerberi D, Bin Abdulhak AA, Giudicessi JR, Ackerman MJ, Kashour T. Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. Mayo Clin Proc Innov Qual Outcomes 2021;5:137-50. [PMID: 33163895 DOI: 10.1016/j.mayocpiqo.2020.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 317 |
Georgiev T. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Rheumatol Int. 2020;40:825-826. [PMID: 32232552 DOI: 10.1007/s00296-020-04570-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 318 |
Varghese GM, John R, Manesh A, Karthik R, Abraham OC. Clinical management of COVID-19. Indian J Med Res 2020;151:401-10. [PMID: 32611911 DOI: 10.4103/ijmr.IJMR_957_20] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 319 |
Chiappalupi S, Salvadori L, Donato R, Riuzzi F, Sorci G. Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19-The Role of RAGE-RAS Crosstalk. Biomolecules 2021;11:876. [PMID: 34204735 DOI: 10.3390/biom11060876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 320 |
Gourieux B, Reisz F, Belmas AS, Danion F, Fourtage M, Nai T, Reiter-Schatz A, Ruch Y, Walther J, Nivoix Y, Michel B. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital. Eur J Hosp Pharm 2021;28:242-7. [PMID: 33239282 DOI: 10.1136/ejhpharm-2020-002449] [Reference Citation Analysis]
|
| 321 |
Klimczak A. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19. World J Stem Cells 2020; 12(9): 1013-1022 [PMID: 33033561 DOI: 10.4252/wjsc.v12.i9.1013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 322 |
Ni Y, Alu A, Lei H, Wang Y, Wu M, Wei X. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Mol Biomed 2021;2:1. [PMID: 34766001 DOI: 10.1186/s43556-020-00015-y] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 323 |
Monari C, Gentile V, Camaioni C, Marino G, Coppola N, Vanvitelli Covid-Group. A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. Life (Basel) 2020;10:E146. [PMID: 32784922 DOI: 10.3390/life10080146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 324 |
Haleem A, Javaid M, Vaishya R, Deshmukh SG. Areas of academic research with the impact of COVID-19. Am J Emerg Med 2020;38:1524-6. [PMID: 32317202 DOI: 10.1016/j.ajem.2020.04.022] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 30.5] [Reference Citation Analysis]
|
| 325 |
Ogunyemi OM, Gyebi GA, Elfiky AA, Afolabi SO, Ogunro OB, Adegunloye AP, Ibrahim IM. Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an in silico perspective. Antivir Chem Chemother 2020;28:2040206620984076. [PMID: 33372806 DOI: 10.1177/2040206620984076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 326 |
Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M, Madan T, Kishore U. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology 2020;225:152008. [PMID: 33130519 DOI: 10.1016/j.imbio.2020.152008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 327 |
Su YB, Kuo MJ, Lin TY, Chien CS, Yang YP, Chou SJ, Leu HB. Cardiovascular manifestation and treatment in COVID-19. J Chin Med Assoc 2020;83:704-9. [PMID: 32433342 DOI: 10.1097/JCMA.0000000000000352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 328 |
Chang WT, Liu PY, Gao ZH, Lee SW, Lee WK, Wu SN. Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I K(M) or I K(DR) and in the Stimulation of I MEP. Front Pharmacol 2020;11:1091. [PMID: 32792942 DOI: 10.3389/fphar.2020.01091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 329 |
Hajivalili M, Hosseini M, Haji-Fatahaliha M. Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. Life Sci 2020;257:118058. [PMID: 32653518 DOI: 10.1016/j.lfs.2020.118058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 330 |
Ross SB, Wilson MG, Papillon-Ferland L, Elsayed S, Wu PE, Battu K, Porter S, Rashidi B, Tamblyn R, Pilote L, Downar J, Bonnici A, Huang A, Lee TC, McDonald EG. COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. J Am Geriatr Soc 2020;68:1636-46. [PMID: 32441771 DOI: 10.1111/jgs.16623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 331 |
Cimolai N. Potentially repurposing adamantanes for COVID‐19. J Med Virol 2020;92:531-2. [DOI: 10.1002/jmv.25752] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 332 |
Tizaoui K, Zidi I, Lee KH, Ghayda RA, Hong SH, Li H, Smith L, Koyanagi A, Jacob L, Kronbichler A, Shin JI. Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19). Int J Biol Sci 2020;16:2906-23. [PMID: 33061805 DOI: 10.7150/ijbs.48812] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 333 |
Prayuenyong P, Kasbekar AV, Baguley DM. Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. Front Public Health 2020;8:252. [PMID: 32574312 DOI: 10.3389/fpubh.2020.00252] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 334 |
Adeel AA. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. Sudan J Paediatr 2020;20:4-9. [PMID: 32528194 DOI: 10.24911/SJP.106-1587122398] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 335 |
Su X, Hu L, You Z, Hu P, Wang L, Zhao B. A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2. Brief Bioinform 2021:bbab526. [PMID: 34965582 DOI: 10.1093/bib/bbab526] [Reference Citation Analysis]
|
| 336 |
Charitos IA, Ballini A, Bottalico L, Cantore S, Passarelli PC, Inchingolo F, D'Addona A, Santacroce L. Special features of SARS-CoV-2 in daily practice. World J Clin Cases 2020; 8(18): 3920-3933 [PMID: 33024749 DOI: 10.12998/wjcc.v8.i18.3920] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 337 |
Hon KL, Leung KKY, Leung AK, Qian SY, Chan VP, Ip P, Wong IC. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. Drugs Context 2020;9:2020-4-15. [PMID: 32655654 DOI: 10.7573/dic.2020-4-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 338 |
Zawawi A, Alghanmi M, Alsaady I, Gattan H, Zakai H, Couper K. The impact of COVID-19 pandemic on malaria elimination. Parasite Epidemiol Control 2020;11:e00187. [PMID: 33102823 DOI: 10.1016/j.parepi.2020.e00187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 339 |
Tahiri Joutei Hassani R, Bennis A. Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed. J Infect Public Health 2020;13:865-7. [PMID: 32451259 DOI: 10.1016/j.jiph.2020.05.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 340 |
Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Health 2021;9:123-7. [PMID: 32838064 DOI: 10.1016/j.cegh.2020.07.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 341 |
Gendrot M, Javelle E, Clerc A, Savini H, Pradines B. Chloroquine as a prophylactic agent against COVID-19? Int J Antimicrob Agents 2020;55:105980. [PMID: 32294495 DOI: 10.1016/j.ijantimicag.2020.105980] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 342 |
Ravikumar N, Nallasamy K, Bansal A, Angurana SK, Basavaraja GV, Sundaram M, Lodha R, Gupta D, Jayashree M; Intensive Care Chapter of Indian Academy of Pediatrics. Novel Coronavirus 2019 (2019-nCoV) Infection: Part I - Preparedness and Management in the Pediatric Intensive Care Unit in Resource-limited Settings. Indian Pediatr 2020;57:324-34. [PMID: 32238612 [PMID: 32238612 DOI: 10.1007/s13312-020-1785-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 343 |
Mudatsir M, Yufika A, Nainu F, Frediansyah A, Megawati D, Pranata A, Mahdani W, Ichsan I, Dhama K, Harapan H. Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick—A Literature Review. Sci Pharm 2020;88:36. [DOI: 10.3390/scipharm88030036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 344 |
Goodarzi P, Mahdavi F, Mirzaei R, Hasanvand H, Sholeh M, Zamani F, Sohrabi M, Tabibzadeh A, Jeda AS, Niya MHK, Keyvani H, Karampoor S. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. Int Immunopharmacol 2020;88:106885. [PMID: 32795893 DOI: 10.1016/j.intimp.2020.106885] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 345 |
Yan D, Ra OH, Yan B. The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Anim Dis 2021;1:15. [PMID: 34778881 DOI: 10.1186/s44149-021-00017-5] [Reference Citation Analysis]
|
| 346 |
Maab H, Mustafa F, Shabbir SJ. Cardiovascular impact of COVID-19: an array of presentations. Acta Biomed 2021;92:e2021021. [PMID: 33988162 DOI: 10.23750/abm.v92i2.10299] [Reference Citation Analysis]
|
| 347 |
Halstead SB, Akkina R. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase. Front Immunol 2020;11:1196. [PMID: 32574267 DOI: 10.3389/fimmu.2020.01196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 348 |
Ray I, Sánchez DF, Robert CA, Robert MP. Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review]]>. IJCTM 2020;Volume 8:7-21. [DOI: 10.2147/ijctm.s269691] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 349 |
Derakhshan MA, Amani A, Faridi-Majidi R. State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2. ACS Appl Mater Interfaces 2021;13:14816-43. [PMID: 33779135 DOI: 10.1021/acsami.0c22381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 350 |
Ali S, Khan AT. Metal-free synthesis of quinoline-2,4-dicarboxylate derivatives using aryl amines and acetylenedicarboxylates through a pseudo three-component reaction. Org Biomol Chem 2021;19:7041-50. [PMID: 34341812 DOI: 10.1039/d1ob01188j] [Reference Citation Analysis]
|
| 351 |
Parlakpinar H, Gunata M. SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. Cell Biochem Funct 2021;39:10-28. [PMID: 32992409 DOI: 10.1002/cbf.3591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 352 |
Morrisette T, Lodise TP, Scheetz MH, Goswami S, Pogue JM, Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. Infect Dis Ther 2020;9:561-72. [PMID: 32740858 DOI: 10.1007/s40121-020-00325-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 353 |
Ali A, Sohaib M, Iqbal S, Hayat K, Khan AU, Rasool MF. Evaluation of COVID-19 Disease Awareness and Its Relation to Mental Health, Dietary Habits, and Physical Activity: A Cross-Sectional Study from Pakistan. Am J Trop Med Hyg 2021:tpmd201451. [PMID: 33690156 DOI: 10.4269/ajtmh.20-1451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 354 |
Serafin MB, Bottega A, Foletto VS, da Rosa TF, Hörner A, Hörner R. Drug repositioning is an alternative for the treatment of coronavirus COVID-19. Int J Antimicrob Agents 2020;55:105969. [PMID: 32278811 DOI: 10.1016/j.ijantimicag.2020.105969] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 355 |
Mukherjee PK, Efferth T, Das B, Kar A, Ghosh S, Singha S, Debnath P, Sharma N, Bhardwaj PK, Haldar PK. Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications. Phytomedicine 2022;98:153930. [PMID: 35114450 DOI: 10.1016/j.phymed.2022.153930] [Reference Citation Analysis]
|
| 356 |
Garrido PF, Calvelo M, Blanco-González A, Veleiro U, Suárez F, Conde D, Cabezón A, Piñeiro Á, Garcia-Fandino R. The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2. Int J Pharm 2020;588:119689. [PMID: 32717282 DOI: 10.1016/j.ijpharm.2020.119689] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 357 |
Wu D, Fang D, Wang R, Deng D, Liao S. Management of Pregnancy during the COVID-19 Pandemic. Glob Chall 2020;:2000052. [PMID: 33173591 DOI: 10.1002/gch2.202000052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 358 |
Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract 2021;75:e13746. [PMID: 32991035 DOI: 10.1111/ijcp.13746] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 359 |
Gorain B, Choudhury H, Molugulu N, Athawale RB, Kesharwani P. Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global Economy. Front Public Health 2020;8:606129. [PMID: 33363098 DOI: 10.3389/fpubh.2020.606129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 360 |
Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, Majumder AA, Nasim T. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther 2020;18:1201-11. [PMID: 32749914 DOI: 10.1080/14787210.2020.1797487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 361 |
Wu B, Lei ZY, Wu KL, He JR, Cao HJ, Fu J, Chen F, Chen Y, Chen B, Zhou XL, Huang T, Wu T, Du YG, Chen SX, Xiao FR, Gao ZL, He J, Lin F, Lin BL. Compare the epidemiological and clinical features of imported and local COVID-19 cases in Hainan, China. Infect Dis Poverty 2020;9:143. [PMID: 33076968 DOI: 10.1186/s40249-020-00755-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 362 |
Pagliano P, Scarpati G, Sellitto C, Conti V, Spera AM, Ascione T, Piazza O, Filippelli A. Experimental Pharmacotherapy for COVID-19: The Latest Advances. J Exp Pharmacol 2021;13:1-13. [PMID: 33442304 DOI: 10.2147/JEP.S255209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 363 |
Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;. [PMID: 32219357 DOI: 10.1001/jamacardio.2020.1096] [Cited by in Crossref: 836] [Cited by in F6Publishing: 751] [Article Influence: 418.0] [Reference Citation Analysis]
|
| 364 |
Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;. [PMID: 32450107 DOI: 10.1016/s0140-6736(20)31180-6] [Cited by in Crossref: 267] [Cited by in F6Publishing: 259] [Article Influence: 133.5] [Reference Citation Analysis]
|
| 365 |
Mandal A, Konala VM, Adapa S, Naramala S, Gayam V. Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. Cureus. 2020;12:e8750. [PMID: 32714688 DOI: 10.7759/cureus.8750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 366 |
Kaddoura M, AlIbrahim M, Hijazi G, Soudani N, Audi A, Alkalamouni H, Haddad S, Eid A, Zaraket H. COVID-19 Therapeutic Options Under Investigation. Front Pharmacol 2020;11:1196. [PMID: 32848795 DOI: 10.3389/fphar.2020.01196] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 367 |
Younis NK, Zareef RO, Al Hassan SN, Bitar F, Eid AH, Arabi M. Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Front Pharmacol 2020;11:597985. [PMID: 33364965 DOI: 10.3389/fphar.2020.597985] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 368 |
Tarrataca L, Dias CM, Haddad DB, De Arruda EF. Flattening the curves: on-off lock-down strategies for COVID-19 with an application to Brazil. J Math Ind 2021;11:2. [PMID: 33432282 DOI: 10.1186/s13362-020-00098-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 369 |
Rammohan A. Post-transplant immunosuppression and COVID-19: From a double whammy to a mixed blessing. World J Transplant 2020; 10(9): 267-276 [PMID: 32995321 DOI: 10.5500/wjt.v10.i9.267] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 370 |
Wang Y, Zhu LQ. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World J Pediatr 2020;16:271-4. [PMID: 32166483 DOI: 10.1007/s12519-020-00353-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 371 |
Alam S, Kamal TB, Sarker MMR, Zhou JR, Rahman SMA, Mohamed IN. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. Front Pharmacol 2021;12:659577. [PMID: 34220503 DOI: 10.3389/fphar.2021.659577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 372 |
Chakraborty D, Debnath F, Biswas S, Bhatta M, Ganguly S, Deb AK, Saha MK, Dutta S. Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review. J Clin Med Res 2020;12:463-71. [PMID: 32849934 DOI: 10.14740/jocmr4241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 373 |
Pergolizzi JV Jr, Magnusson P, LeQuang JA, Breve F, Paladini A, Rekatsina M, Yeam CT, Imani F, Saltelli G, Taylor R Jr, Wollmuth C, Varrassi G. The Current Clinically Relevant Findings on COVID-19 Pandemic. Anesth Pain Med 2020;10:e103819. [PMID: 32754437 DOI: 10.5812/aapm.103819] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 374 |
Pourghasemi HR, Pouyan S, Heidari B, Farajzadeh Z, Fallah Shamsi SR, Babaei S, Khosravi R, Etemadi M, Ghanbarian G, Farhadi A, Safaeian R, Heidari Z, Tarazkar MH, Tiefenbacher JP, Azmi A, Sadeghian F. Spatial modeling, risk mapping, change detection, and outbreak trend analysis of coronavirus (COVID-19) in Iran (days between February 19 and June 14, 2020). Int J Infect Dis 2020;98:90-108. [PMID: 32574693 DOI: 10.1016/j.ijid.2020.06.058] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 375 |
Lauretani F, Ravazzoni G, Roberti MF, Longobucco Y, Adorni E, Grossi M, De Iorio A, La Porta U, Fazio C, Gallini E, Federici R, Salvi M, Ciarrocchi E, Rossi F, Bergamin M, Bussolati G, Grieco I, Broccoli F, Zucchini I, Ielo G, Morganti S, Artoni A, Arisi A, Tagliaferri S, Maggio M. Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications. Acta Biomed 2020;91:150-68. [PMID: 32420939 DOI: 10.23750/abm.v91i2.9629] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
| 376 |
Yu R, Chen L, Lan R, Shen R, Li P. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents 2020;56:106012. [PMID: 32389723 DOI: 10.1016/j.ijantimicag.2020.106012] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 42.5] [Reference Citation Analysis]
|
| 377 |
Sun X, Li S, Li K, Hu X. Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19). Aging Med (Milton) 2020;3:98-101. [PMID: 32666027 DOI: 10.1002/agm2.12104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 378 |
Gao G, Wang A, Wang S, Qian F, Chen M, Yu F, Zhang J, Wang X, Ma X, Zhao T, Zhang F, Chen Z. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. J Acquir Immune Defic Syndr 2020;85:239-43. [PMID: 32740371 DOI: 10.1097/QAI.0000000000002452] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 379 |
Thakar A, Panda S, Sakthivel P, Brijwal M, Dhakad S, Choudekar A, Kanodia A, Bhatnagar S, Mohan A, Maulik SK, Dar L. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial. Indian J Med Res 2021;153:151-8. [PMID: 33818472 DOI: 10.4103/ijmr.IJMR_3665_20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 380 |
Mann R, Perisetti A, Gajendran M, Gandhi Z, Umapathy C, Goyal H. Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. Front Med (Lausanne). 2020;7:581521. [PMID: 33282890 DOI: 10.3389/fmed.2020.581521] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 381 |
Gasperetti A, Biffi M, Duru F, Schiavone M, Ziacchi M, Mitacchione G, Lavalle C, Saguner A, Lanfranchi A, Casalini G, Tocci M, Fabbricatore D, Salghetti F, Mariani MV, Busana M, Bellia A, Cogliati CB, Viale P, Antinori S, Galli M, Galiè N, Tondo C, Forleo GB. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. Europace 2020;22:1855-63. [PMID: 32971536 DOI: 10.1093/europace/euaa216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 382 |
Porras-Villamil JF, Olivera MJ, Ríos-Camargo NK. The First Few Hundred Cases for Coronavirus Disease 2019 (COVID-19) in Colombia. Iran J Public Health 2020;49:48-56. [PMID: 34268205 DOI: 10.18502/ijph.v49iS1.3669] [Reference Citation Analysis]
|
| 383 |
Huang F, Li Y, Leung EL, Liu X, Liu K, Wang Q, Lan Y, Li X, Yu H, Cui L, Luo H, Luo L. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). Pharmacol Res 2020;158:104929. [PMID: 32442720 DOI: 10.1016/j.phrs.2020.104929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 384 |
Luo Z, Ang MJY, Chan SY, Yi Z, Goh YY, Yan S, Tao J, Liu K, Li X, Zhang H, Huang W, Liu X. Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community. Research (Wash D C) 2020;2020:6925296. [PMID: 32607499 DOI: 10.34133/2020/6925296] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 385 |
Abuin P, Anderson A, Ferramosca A, Hernandez-Vargas EA, Gonzalez AH. Dynamical characterization of antiviral effects in COVID-19. Annu Rev Control 2021. [PMID: 34093069 DOI: 10.1016/j.arcontrol.2021.05.001] [Reference Citation Analysis]
|
| 386 |
Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. Lupus Sci Med. 2020;7:e000396. [PMID: 32341791 DOI: 10.1136/lupus-2020-000396] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 387 |
Alhasan A, Audah L, Ibrahim I, Al-sharaa A, Al-ogaili AS, M. Mohammed J. A case-study to examine doctors’ intentions to use IoT healthcare devices in Iraq during COVID-19 pandemic. IJPCC 2020;ahead-of-print. [DOI: 10.1108/ijpcc-10-2020-0175] [Cited by in Crossref: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 388 |
Picchianti Diamanti A, Rosado MM, Nicastri E, Sesti G, Pioli C, Laganà B. Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. Front Immunol 2021;12:708848. [PMID: 34659200 DOI: 10.3389/fimmu.2021.708848] [Reference Citation Analysis]
|
| 389 |
Barati F, Pouresmaieli M, Ekrami E, Asghari S, Ziarani FR, Mamoudifard M. Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. Biol Proced Online 2020;22:15. [PMID: 32754003 DOI: 10.1186/s12575-020-00129-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 390 |
Vitte J, Michel M, Mezouar S, Diallo AB, Boumaza A, Mege JL, Desnues B. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. Front Immunol 2020;11:2159. [PMID: 32983179 DOI: 10.3389/fimmu.2020.02159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 391 |
Pereira LJ, Pereira CV, Murata RM, Pardi V, Pereira-Dourado SM. Biological and social aspects of Coronavirus Disease 2019 (COVID-19) related to oral health. Braz Oral Res 2020;34:e041. [PMID: 32401931 DOI: 10.1590/1807-3107bor-2020.vol34.0041] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 392 |
Udofia IA, Gbayo KO, Oloba-Whenu OA, Ogunbayo TB, Isanbor C. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV. Netw Model Anal Health Inform Bioinform 2021;10:22. [PMID: 33786291 DOI: 10.1007/s13721-021-00299-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 393 |
Jethani B, Gupta M, Wadhwani P, Thomas R, Balakrishnan T, Mathew G, Mathur M, Rao BP, Shukla D, Khullar A, Khera M, Sharma H, Kumar R, Kumar S, Jaggi S, Sinha R, Rawal K, Kapoor A, Manchanda RK. Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study. Homeopathy 2021;110:86-93. [PMID: 33567460 DOI: 10.1055/s-0040-1718584] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 394 |
Kochav SM, Coromilas E, Nalbandian A, Ranard LS, Gupta A, Chung MK, Gopinathannair R, Biviano AB, Garan H, Wan EY. Cardiac Arrhythmias in COVID-19 Infection. Circ Arrhythm Electrophysiol 2020;13:e008719. [PMID: 32434385 DOI: 10.1161/CIRCEP.120.008719] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 23.5] [Reference Citation Analysis]
|
| 395 |
Beck-Friis J, Leach S, Omerovic E, Zeijlon R, Gisslen M, Yilmaz A. No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. PLoS One 2021;16:e0256035. [PMID: 34398893 DOI: 10.1371/journal.pone.0256035] [Reference Citation Analysis]
|
| 396 |
Coban MA, Morrison J, Maharjan S, Hernandez Medina DH, Li W, Zhang YS, Freeman WD, Radisky ES, Le Roch KG, Weisend CM, Ebihara H, Caulfield TR. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. Biomolecules 2021;11:787. [PMID: 34071060 DOI: 10.3390/biom11060787] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 397 |
Pasquereau S, Nehme Z, Haidar Ahmad S, Daouad F, Van Assche J, Wallet C, Schwartz C, Rohr O, Morot-Bizot S, Herbein G. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses 2021;13:354. [PMID: 33672333 DOI: 10.3390/v13020354] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 398 |
Keizman E, Ram E, Kachel E, Sternik L, Raanani E. The impact of COVID-19 pandemic on cardiac surgery in Israel. J Cardiothorac Surg 2020;15:294. [PMID: 33008486 DOI: 10.1186/s13019-020-01342-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 399 |
Hossain MJ, Rahman SMA. Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. Expert Rev Anti Infect Ther 2021;19:1009-27. [PMID: 33355520 DOI: 10.1080/14787210.2021.1864327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 400 |
Karadag AS, Aslan Kayıran M, Lotti T, Wollina U. Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. Dermatol Ther 2020;33:e13686. [PMID: 32458530 DOI: 10.1111/dth.13686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 401 |
Niriella MA, Ediriweera DS, De Silva AP, Premarathne R, Balasooriya P, Duminda KD, Malavige NG, Wanigasuriya K, Lekamwasam S, Kularathne SA, Siribaddana S, de Silva HJ, Jayasinghe S. Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial. Trials 2020;21:748. [PMID: 32854751 DOI: 10.1186/s13063-020-04659-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 402 |
Jiao Y, Kong N, Wang H, Sun D, Dong S, Chen X, Zheng H, Tong W, Yu H, Yu L, Huang Y, Wang H, Sui B, Zhao L, Liao Y, Zhang W, Tong G, Shan T. PABPC4 Broadly Inhibits Coronavirus Replication by Degrading Nucleocapsid Protein through Selective Autophagy. Microbiol Spectr 2021;9:e0090821. [PMID: 34612687 DOI: 10.1128/Spectrum.00908-21] [Reference Citation Analysis]
|
| 403 |
Chan W, He B, Wang X, He ML. Pandemic COVID-19: Current status and challenges of antiviral therapies. Genes Dis 2020;7:502-19. [PMID: 32837984 DOI: 10.1016/j.gendis.2020.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 404 |
Lee SY, Lei B, Mallick B. Estimation of COVID-19 spread curves integrating global data and borrowing information. PLoS One 2020;15:e0236860. [PMID: 32726361 DOI: 10.1371/journal.pone.0236860] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 405 |
Paolino G, Mercuri SR, Bearzi P, Mattozzi C. Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation. Dermatol Ther 2020;33:e13537. [PMID: 32385891 DOI: 10.1111/dth.13537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 406 |
Patel D, Athar M, Jha PC. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2. J Biomol Struct Dyn 2020;:1-11. [PMID: 33200683 DOI: 10.1080/07391102.2020.1844804] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 407 |
Barkat MA, Kaushik P, Barkat HA, Khan MI, Hadi HA. Phytoconstituents in the Management of Covid-19: Demystifying the Fact. Drug Res (Stuttg) 2022. [PMID: 34979573 DOI: 10.1055/a-1697-5365] [Reference Citation Analysis]
|
| 408 |
Yuan H, Cao X, Ji X, Du F, He J, Zhou X, Xie Y, Zhu Y. An Updated Understanding of the Current Emerging Respiratory Infection: COVID-19. Biomed Res Int 2020;2020:6870512. [PMID: 33134384 DOI: 10.1155/2020/6870512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 409 |
Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432. [PMID: 32269046 DOI: 10.1136/bmj.m1432] [Cited by in Crossref: 189] [Cited by in F6Publishing: 170] [Article Influence: 94.5] [Reference Citation Analysis]
|
| 410 |
Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, Chen Y, Han Y. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020;106:1132-1141. [PMID: 32354800 DOI: 10.1136/heartjnl-2020-317056] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 60.5] [Reference Citation Analysis]
|
| 411 |
Shorey S, Chan V. Lessons from past epidemics and pandemics and a way forward for pregnant women, midwives and nurses during COVID-19 and beyond: A meta-synthesis. Midwifery 2020;90:102821. [PMID: 32847770 DOI: 10.1016/j.midw.2020.102821] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 412 |
Gomaa AA, Mohamed HS, Abd-Ellatief RB, Gomaa MA. Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly. Inflammopharmacology 2021;29:1033-48. [PMID: 34224069 DOI: 10.1007/s10787-021-00841-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 413 |
Chen Y, Li MX, Lu GD, Shen HM, Zhou J. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. Int J Biol Sci 2021;17:1538-46. [PMID: 33907517 DOI: 10.7150/ijbs.59547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 414 |
Shetty RM, Namachivayam A. Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. Indian J Crit Care Med 2021;25:441-52. [PMID: 34045812 DOI: 10.5005/jp-journals-10071-23773] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 415 |
Ferreira A, Oliveira-E-Silva A, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol 2021;93:755-9. [PMID: 32644224 DOI: 10.1002/jmv.26286] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 416 |
Aherfi S, Pradines B, Devaux C, Honore S, Colson P, Scola B, Raoult D. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiol 2021;16:1341-70. [PMID: 34755538 DOI: 10.2217/fmb-2021-0019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 417 |
Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W, Zervos M; Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 2020;97:396-403. [PMID: 32623082 DOI: 10.1016/j.ijid.2020.06.099] [Cited by in Crossref: 259] [Cited by in F6Publishing: 236] [Article Influence: 129.5] [Reference Citation Analysis]
|
| 418 |
Casey JD, Johnson NJ, Semler MW, Collins SP, Aggarwal NR, Brower RG, Chang SY, Eppensteiner J, Filbin M, Gibbs KW, Ginde AA, Gong MN, Harrell F, Hayden DL, Hough CL, Khan A, Leither LM, Moss M, Oldmixon CF, Park PK, Reineck LA, Ringwood NJ, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Torr DK, Weissman A, Lindsell CJ, Rice TW, Thompson BT, Brown SM, Self WH. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. Ann Am Thorac Soc 2020;17:1144-53. [PMID: 32492354 DOI: 10.1513/AnnalsATS.202005-478SD] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 419 |
[DOI: 10.1101/2020.04.08.20054551] [Cited by in Crossref: 28] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
|
| 420 |
Patil VM, Singhal S, Masand N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. Life Sci 2020;254:117775. [PMID: 32418894 DOI: 10.1016/j.lfs.2020.117775] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 421 |
Tariq A, Mateen RM, Afzal MS, Saleem M. Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. Int J Infect Dis 2020;98:166-75. [PMID: 32579907 DOI: 10.1016/j.ijid.2020.06.063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 422 |
Khan G, Sheek-Hussein M, Al Suwaidi AR, Idris K, Abu-Zidan FM. Novel coronavirus pandemic: A global health threat. Turk J Emerg Med 2020;20:55-62. [PMID: 32587923 DOI: 10.4103/2452-2473.285016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 423 |
Benucci M, Damiani A, Infantino M, Manfredi M, Quartuccio L. Médicaments rhumatologiques pour le traitement de l’infection par le COVID-19. Rev Rhum Ed Fr 2020;87:150-2. [PMID: 32355446 DOI: 10.1016/j.rhum.2020.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 424 |
Hussain K, Ambreen G, Muzammil M, Raza SS, Ali U. Pharmacy services during COVID-19 pandemic: experience from a tertiary care teaching hospital in Pakistan. J Pharm Policy Pract 2020;13:74. [PMID: 33292772 DOI: 10.1186/s40545-020-00277-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 425 |
Chen J, Ali F, Khan I, Zhu YZ. Recent progress in the development of potential drugs against SARS-CoV-2. Curr Res Pharmacol Drug Discov 2021;2:100057. [PMID: 34870155 DOI: 10.1016/j.crphar.2021.100057] [Reference Citation Analysis]
|
| 426 |
Abbasifard M, Khorramdelazad H. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life Sci 2020;257:118097. [PMID: 32679148 DOI: 10.1016/j.lfs.2020.118097] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 427 |
El Boussadani B, Benajiba C, Aajal A, Ait Brik A, Ammour O, El Hangouch J, Oussama O, Oussama B, Tahiri N, Raissuni Z. [COVID-19 pandemia: Impact on the cariovascular system. Data of 1st April 2020]. Ann Cardiol Angeiol (Paris) 2020;69:107-14. [PMID: 32303363 DOI: 10.1016/j.ancard.2020.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 428 |
Zuccon W, Comassi P, Adriani L, Bergamaschini G, Bertin E, Borromeo R, Corti S, De Petri F, Dolci F, Galmozzi A, Gigliotti A, Gualdoni L, Guerra C, Khosthiova A, Leati G, Lupi G, Moscato P, Perotti V, Piantelli M, Ruini A, Sportelli S, Susca M, Troiano C, Benelli G, Buscarini E, Canetta C, Merli G, Scartabellati A, Melilli B S C G, Sfogliarini R, Pellegatta G, Viganò G. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy. Am J Emerg Med 2021;45:156-61. [PMID: 33046317 DOI: 10.1016/j.ajem.2020.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 429 |
Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020;33. [PMID: 32580969 DOI: 10.1128/cmr.00028-20] [Cited by in Crossref: 222] [Cited by in F6Publishing: 125] [Article Influence: 111.0] [Reference Citation Analysis]
|
| 430 |
Fakher S, Peymani P, Ghavami S, Mokarram P. The Role of Autophagy in Respiratory Complications of COVID-19. Shiraz E-Med J 2020;21. [DOI: 10.5812/semj.102967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 431 |
Qin L, Sun Q, Wang Y, Wu KF, Chen M, Shia BC, Wu SY. Prediction of Number of Cases of 2019 Novel Coronavirus (COVID-19) Using Social Media Search Index. Int J Environ Res Public Health 2020;17:E2365. [PMID: 32244425 DOI: 10.3390/ijerph17072365] [Cited by in Crossref: 72] [Cited by in F6Publishing: 38] [Article Influence: 36.0] [Reference Citation Analysis]
|
| 432 |
Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, Chouchana L, Rocher F, Drici MD; French Network of Pharmacovigilance Centers. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie 2020;75:371-9. [PMID: 32418730 DOI: 10.1016/j.therap.2020.05.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 24.0] [Reference Citation Analysis]
|
| 433 |
Manchanda Y, Das S, De A. Coronavirus Disease of 2019 (COVID-19) Facts and Figures: What Every Dermatologist Should Know at this Hour of Need. Indian J Dermatol 2020;65:251-8. [PMID: 32831363 DOI: 10.4103/ijd.IJD_360_20] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 434 |
Shah A. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. Front Immunol 2020;11:1021. [PMID: 32574259 DOI: 10.3389/fimmu.2020.01021] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 435 |
Ferranti JF, Rodriguez IS, Motta E, Johnston C, Carvalho WBB, Delgado AF. Beyond ventilatory support: challenges in general practice and in the treatment of critically Ill children and adolescents with SARS-CoV-2 infection. Rev Assoc Med Bras (1992) 2020;66:521-7. [PMID: 32578790 DOI: 10.1590/1806-9282.66.4.521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 436 |
Li H, Liu Z, Ge J. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. J Cell Mol Med 2020;24:6558-70. [PMID: 32320516 DOI: 10.1111/jcmm.15364] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 437 |
Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents 2020;56:106028. [PMID: 32450198 DOI: 10.1016/j.ijantimicag.2020.106028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 24.5] [Reference Citation Analysis]
|
| 438 |
Kumar S, Zhi K, Mukherji A, Gerth K. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. Viruses 2020;12:E486. [PMID: 32357553 DOI: 10.3390/v12050486] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 27.5] [Reference Citation Analysis]
|
| 439 |
ElHawary H, Salimi A, Diab N, Smith L. Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers. Infect Dis (Auckl) 2020;13:1178633720962935. [PMID: 33110348 DOI: 10.1177/1178633720962935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 440 |
Little C, Cosetti MK. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. Laryngoscope 2021;131:1626-32. [PMID: 33491234 DOI: 10.1002/lary.29424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 441 |
Rajaiah R, Abhilasha KV, Shekar MA, Vogel SN, Vishwanath BS. Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. Cell Immunol 2020;358:104240. [PMID: 33137649 DOI: 10.1016/j.cellimm.2020.104240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 442 |
Rahman AK, Purdy AG, Ender PT. COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. Case Rep Infect Dis 2020;2020:8822753. [PMID: 33123391 DOI: 10.1155/2020/8822753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 443 |
Nessaibia I, Siciliano D, Tahraoui A. Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19? Int J Health Plann Manage 2020;35:1311-3. [PMID: 32914465 DOI: 10.1002/hpm.3057] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 444 |
Crosby JC, Heimann MA, Burleson SL, Anzalone BC, Swanson JF, Wallace DW, Greene CJ. COVID-19: A review of therapeutics under investigation. J Am Coll Emerg Physicians Open 2020. [PMID: 32838367 DOI: 10.1002/emp2.12081] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 445 |
Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou M, Drakoulis N, Dumanov JM, Tutelyan VA, Onischenko GG, Aschner M, Spandidos DA, Calina D. A new threat from an old enemy: Re‑emergence of coronavirus (Review). Int J Mol Med 2020;45:1631-43. [PMID: 32236624 DOI: 10.3892/ijmm.2020.4555] [Cited by in Crossref: 30] [Cited by in F6Publishing: 92] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 446 |
Mahajan A, Hirsch JA. Novel Coronavirus: What Neuroradiologists as Citizens of the World Need to Know. AJNR Am J Neuroradiol 2020;41:552-4. [PMID: 32198164 DOI: 10.3174/ajnr.A6526] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 447 |
Dehelean CA, Lazureanu V, Coricovac D, Mioc M, Oancea R, Marcovici I, Pinzaru I, Soica C, Tsatsakis AM, Cretu O. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. J Clin Med 2020;9:E2084. [PMID: 32630746 DOI: 10.3390/jcm9072084] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 448 |
Beura S, Chetti P. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2. J Biomol Struct Dyn 2021;39:3747-59. [PMID: 32448039 DOI: 10.1080/07391102.2020.1772111] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 449 |
Yadullahi Mir WA, Siddiqui AH, Valecha G, Patel S, Ayub F, Upadhyay R, Alhajri SA, Gaire S, Shrestha DB. A Narrative Review of Existing Options for COVID-19-Specific Treatments. Adv Virol 2021;2021:8554192. [PMID: 34804163 DOI: 10.1155/2021/8554192] [Reference Citation Analysis]
|
| 450 |
Faden YA, Alghilan NA, Alawami SH, Alsulmi ES, Alsum HA, Katib YA, Sabr YS, Tahir FH, Bondagji NS. Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019. Saudi Med J 2020;41:779-90. [PMID: 32789417 DOI: 10.15537/smj.2020.8.25222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 451 |
Thevarajan I, Buising KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust 2020;213:134-9. [PMID: 32677734 DOI: 10.5694/mja2.50698] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 452 |
Tiwari V. De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2. Biol Open 2020;9:bio054056. [PMID: 32878881 DOI: 10.1242/bio.054056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 453 |
Sivasankarapillai VS, Pillai AM, Rahdar A, Sobha AP, Das SS, Mitropoulos AC, Mokarrar MH, Kyzas GZ. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. Nanomaterials (Basel) 2020;10:E852. [PMID: 32354113 DOI: 10.3390/nano10050852] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 454 |
Makvandi P, Chen M, Sartorius R, Zarrabi A, Ashrafizadeh M, Dabbagh Moghaddam F, Ma J, Mattoli V, Tay FR. Endocytosis of abiotic nanomaterials and nanobiovectors: Inhibition of membrane trafficking. Nano Today 2021;40:101279. [PMID: 34518771 DOI: 10.1016/j.nantod.2021.101279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 455 |
Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv 2020;11:245-68. [PMID: 32397911 DOI: 10.4155/tde-2020-0035] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 24.5] [Reference Citation Analysis]
|
| 456 |
Hajjar LA, Costa IBSDS, Rizk SI, Biselli B, Gomes BR, Bittar CS, de Oliveira GQ, de Almeida JP, de Oliveira Bello MV, Garzillo C, Leme AC, Elena M, Val F, de Almeida Lopes M, Lacerda MVG, Ramires JAF, Kalil Filho R, Teboul JL, Landoni G. Intensive care management of patients with COVID-19: a practical approach. Ann Intensive Care 2021;11:36. [PMID: 33604873 DOI: 10.1186/s13613-021-00820-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 457 |
Iwasaka S, Shono Y, Tokuda K, Nakashima K, Yamamoto Y, Maki J, Nagasaki Y, Shimono N, Akahoshi T, Taguchi T. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. J Infect Chemother 2020;26:1319-23. [PMID: 32893123 DOI: 10.1016/j.jiac.2020.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 458 |
Kalinova D, Rashkov R. Rheumatological aspects of pathogenesis and treatment of COVID-19 infection. Reumatologia 2020;58:231-5. [PMID: 32921830 DOI: 10.5114/reum.2020.98435] [Reference Citation Analysis]
|
| 459 |
Scala S, Pacelli R. Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. Front Immunol 2020;11:1201. [PMID: 32574268 DOI: 10.3389/fimmu.2020.01201] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 460 |
Tao Y, Tang LV, Hu Y. Treatments in the COVID-19 pandemic: an update on clinical trials. Expert Opin Emerg Drugs 2020;25:81-8. [PMID: 32447996 DOI: 10.1080/14728214.2020.1773431] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 461 |
Miao Z, Cai Y, Meng J, Zhou W. Therapeutic Options and Treatment Strategies Against COVID-19 in China. Curr Org Synth 2020;17:413-4. [PMID: 33003993 DOI: 10.2174/157017941706200925091306] [Reference Citation Analysis]
|
| 462 |
Garg I, Srivastava S, Dogra V, Bargotya M, Bhattar S, Gupta U, Jain S, Hussain J, Hembrom AA, Ghosh N, Kumar V, Kumar B, Varshney R, Ganju L. Potential association of COVID-19 and ABO blood group: An Indian study. Microb Pathog 2021;158:105008. [PMID: 34087389 DOI: 10.1016/j.micpath.2021.105008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 463 |
Chen R, Lan Z, Ye J, Pang L, Liu Y, Wu W, Qin X, Guo Y, Zhang P. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Front Immunol 2021;12:589095. [PMID: 33995341 DOI: 10.3389/fimmu.2021.589095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 464 |
Mégarbane B. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Clin Toxicol (Phila) 2021;59:70-1. [PMID: 32237918 DOI: 10.1080/15563650.2020.1748194] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 465 |
Saleemi MA, Ahmad B, Benchoula K, Vohra MS, Mea HJ, Chong PP, Palanisamy NK, Wong EH. Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. Infect Genet Evol 2020;85:104583. [PMID: 33035643 DOI: 10.1016/j.meegid.2020.104583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 466 |
Hijikata A, Shionyu-Mitsuyama C, Nakae S, Shionyu M, Ota M, Kanaya S, Shirai T. Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs. FEBS Lett 2020;594:1960-73. [PMID: 32379896 DOI: 10.1002/1873-3468.13806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 467 |
Janik E, Niemcewicz M, Podogrocki M, Saluk-Bijak J, Bijak M. Existing Drugs Considered as Promising in COVID-19 Therapy. Int J Mol Sci 2021;22:5434. [PMID: 34063964 DOI: 10.3390/ijms22115434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 468 |
Wang D, Huang J, Yeung AWK, Tzvetkov NT, Horbańczuk JO, Willschke H, Gai Z, Atanasov AG. The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. Processes 2020;8:937. [DOI: 10.3390/pr8080937] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 469 |
Ghasemiyeh P, Mohammadi-Samani S. COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. Heart Lung 2020;49:763-73. [PMID: 32980626 DOI: 10.1016/j.hrtlng.2020.08.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 470 |
Tang D, Li J, Zhang R, Kang R, Klionsky DJ. Chloroquine in fighting COVID-19: good, bad, or both? Autophagy 2020;16:2273-5. [PMID: 32713288 DOI: 10.1080/15548627.2020.1796014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 471 |
Dongala T, Ettaboina SK, Katari NK. A Novel RP-HPLC-DAD Method Development for Anti-Malarial and COVID-19 Hydroxy Chloroquine Sulfate Tablets and Profiling of In-Vitro Dissolution in Multimedia. Res Sq 2020:rs. [PMID: 32702733 DOI: 10.21203/rs.3.pex-880/v2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 472 |
van Gorp G, Sanders P, van Waardenburg DA, Engel M. COVID-19 pneumonia successfully managed with high-flow nasal cannula in a 15-year-old boy. BMJ Case Rep 2021;14:e239682. [PMID: 33846181 DOI: 10.1136/bcr-2020-239682] [Reference Citation Analysis]
|
| 473 |
Lima-Morales R, Méndez-Hernández P, Flores YN, Osorno-Romero P, Sancho-Hernández CR, Cuecuecha-Rugerio E, Nava-Zamora A, Hernández-Galdamez DR, Romo-Dueñas DK, Salmerón J. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. Int J Infect Dis 2021;105:598-605. [PMID: 33578014 DOI: 10.1016/j.ijid.2021.02.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 474 |
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113. [PMID: 32289115 DOI: 10.1016/j.jhepr.2020.100113] [Cited by in Crossref: 203] [Cited by in F6Publishing: 201] [Article Influence: 101.5] [Reference Citation Analysis]
|
| 475 |
Muthuramalingam P, Jeyasri R, Valliammai A, Selvaraj A, Karthika C, Gowrishankar S, Pandian SK, Ramesh M, Chen JT. Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach. Genomics 2020;112:4486-504. [PMID: 32771622 DOI: 10.1016/j.ygeno.2020.08.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 476 |
Inchingolo AD, Dipalma G, Inchingolo AM, Malcangi G, Santacroce L, D'Oria MT, Isacco CG, Bordea IR, Candrea S, Scarano A, Morandi B, Del Fabbro M, Farronato M, Tartaglia GM, Balzanelli MG, Ballini A, Nucci L, Lorusso F, Taschieri S, Inchingolo F. The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. Antioxidants (Basel) 2021;10:881. [PMID: 34072708 DOI: 10.3390/antiox10060881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 477 |
Oymak Y, Karapinar TH, Devrim İ. Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine? J Pediatr Hematol Oncol 2021;43:35-6. [PMID: 32496442 DOI: 10.1097/MPH.0000000000001864] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 478 |
Rebeaud ME, Zores F. SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment. Front Med (Lausanne) 2020;7:184. [PMID: 32391371 DOI: 10.3389/fmed.2020.00184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 479 |
Tompa DR, Immanuel A, Srikanth S, Kadhirvel S. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. Int J Biol Macromol 2021;172:524-41. [PMID: 33454328 DOI: 10.1016/j.ijbiomac.2021.01.076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 480 |
Ho TC, Wang YH, Chen YL, Tsai WC, Lee CH, Chuang KP, Chen YA, Yuan CH, Ho SY, Yang MH, Tyan YC. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19. Pathogens. 2021;10. [PMID: 33671315 DOI: 10.3390/pathogens10020217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 481 |
Zarandi PK, Zinatizadeh MR, Zinatizadeh M, Yousefi MH, Rezaei N. SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. Biomed Pharmacother 2021;137:111352. [PMID: 33550050 DOI: 10.1016/j.biopha.2021.111352] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 482 |
Kiedrowski M, Kapala P, Kiedrowska M, Skoczynska A, Czerw A, Deptała A. Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Med Hypotheses 2021;146:110434. [PMID: 33277106 DOI: 10.1016/j.mehy.2020.110434] [Reference Citation Analysis]
|
| 483 |
Peng W, Wu H, Tan Y, Li M, Yang D, Li S. Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. Life Sci 2020;262:118496. [PMID: 32987060 DOI: 10.1016/j.lfs.2020.118496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 484 |
de Oliveira VM, da Rocha MN, Magalhães EP, da Silva Mendes FR, Marinho MM, de Menezes RRPPB, Sampaio TL, Dos Santos HS, Martins AMC, Marinho ES. Computational approach towards the design of artemisinin-thymoquinone hybrids against main protease of SARS-COV-2. Futur J Pharm Sci 2021;7:185. [PMID: 34514004 DOI: 10.1186/s43094-021-00334-z] [Reference Citation Analysis]
|
| 485 |
Singh P, Tripathi MK, Yasir M, Khare R, Tripathi MK, Shrivastava R. Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. Plant Foods Hum Nutr 2020;75:458-66. [PMID: 33037564 DOI: 10.1007/s11130-020-00861-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 486 |
Alanagreh L, Alzoughool F, Atoum M. Risk of using hydroxychloroquine as a treatment of COVID-19. Int J Risk Saf Med 2020;31:111-6. [PMID: 32474476 DOI: 10.3233/JRS-200024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 487 |
Aljofan M, Gaipov A. Chloroquine and COVID-19: A Light at the End of the Tunnel, or is it Another Train? Electron J Gen Med 2020;17:em207. [DOI: 10.29333/ejgm/7863] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 488 |
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323:1824-1836. [PMID: 32282022 DOI: 10.1001/jama.2020.6019] [Cited by in Crossref: 698] [Cited by in F6Publishing: 876] [Article Influence: 349.0] [Reference Citation Analysis]
|
| 489 |
Kumar D, Trivedi N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomed Pharmacother 2021;139:111642. [PMID: 33940506 DOI: 10.1016/j.biopha.2021.111642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 490 |
Ahmad SI. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. Med Hypotheses 2020;142:109754. [PMID: 32438240 DOI: 10.1016/j.mehy.2020.109754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 491 |
Defo Deeh PB, Kayri V, Orhan C, Sahin K. Status of Novel Coronavirus Disease 2019 (COVID-19) and Animal Production. Front Vet Sci 2020;7:586919. [PMID: 33251268 DOI: 10.3389/fvets.2020.586919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 492 |
Premkumar M, Kedarisetty CK. Cytokine Storm of COVID-19 and Its Impact on Patients with and without Chronic Liver Disease. J Clin Transl Hepatol 2021;9:256-64. [PMID: 34007808 DOI: 10.14218/JCTH.2021.00055] [Reference Citation Analysis]
|
| 493 |
Ikonne EU, Ikpeazu VO, Ugbogu OC, Emmanuel O, Nwakuche IP, Iweala EJ, Ugbogu EA. A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. Drug Metab Pers Ther 2021. [PMID: 33818026 DOI: 10.1515/dmpt-2020-0184] [Reference Citation Analysis]
|
| 494 |
Farina N, Ramirez GA, De Lorenzo R, Di Filippo L, Conte C, Ciceri F, Manfredi AA, Rovere-Querini P. COVID-19: Pharmacology and kinetics of viral clearance. Pharmacol Res 2020;161:105114. [PMID: 32758635 DOI: 10.1016/j.phrs.2020.105114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 495 |
Yu X, Xu X, Wu T, Huang W, Xu C, Xie W, Long X. APOA1 Level is Negatively Correlated with the Severity of COVID-19. IJGM 2022;Volume 15:689-98. [DOI: 10.2147/ijgm.s332956] [Reference Citation Analysis]
|
| 496 |
Hosseini M, Chen W, Xiao D, Wang C. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. Precis Clin Med 2021;4:1-16. [PMID: 33842834 DOI: 10.1093/pcmedi/pbab001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 497 |
Chen PF, Yu XX, Liu YP, Ren D, Shen M, Huang BS, Gao JL, Huang ZY, Wu M, Wang WY, Chen L, Shi X, Wang ZQ, Liu YX, Liu L, Liu Y. Virus load and virus shedding of SARS-CoV-2 and their impact on patient outcomes. World J Clin Cases 2020; 8(24): 6252-6263 [PMID: 33392306 DOI: 10.12998/wjcc.v8.i24.6252] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 498 |
Ayhan M, Odabas H, Turan N, Ozyukseler DT, Kostek O, Alkan G, Abamor E, Yildirim ME. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother 2021;:1-10. [PMID: 34032198 DOI: 10.1080/1120009X.2021.1923153] [Reference Citation Analysis]
|
| 499 |
Si Y, Xu X, Hu Y, Si H, Zhai H. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19. Chem Biol Drug Des 2021;97:978-83. [PMID: 33386649 DOI: 10.1111/cbdd.13822] [Reference Citation Analysis]
|
| 500 |
Dhaiban AK, Jabbar BK. An optimal control model of COVID-19 pandemic: a comparative study of five countries. OPSEARCH 2021;58:790-809. [DOI: 10.1007/s12597-020-00491-4] [Reference Citation Analysis]
|
| 501 |
Pawar HA, Pawar AH, Pawar SA, Pawar PA. CORONAVIRUS and COVID-19: A Systematic Review and Perspective. CDTH 2020;15:423-35. [DOI: 10.2174/1574885515999200719142835] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 502 |
Manivannan E, Karthikeyan C, Moorthy NSHN, Chaturvedi SC. The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19. Front Pharmacol 2021;12:584940. [PMID: 34025393 DOI: 10.3389/fphar.2021.584940] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 503 |
Hsia BC, Greige N, Quiroz JA, Khokhar AS, Daily J, Di Biase L, Ferrick KJ, Fisher JD, Krumerman A. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. J Interv Card Electrophysiol 2020;59:337-45. [PMID: 32654098 DOI: 10.1007/s10840-020-00822-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 504 |
Bahlol M, Dewey RS. Pandemic preparedness of community pharmacies for COVID-19. Res Social Adm Pharm 2021;17:1888-96. [PMID: 32417070 DOI: 10.1016/j.sapharm.2020.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 505 |
Bouazza B, Hadj-Said D, Pescatore KA, Chahed R. Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19? Tuberc Respir Dis (Seoul) 2021;84:22-34. [PMID: 33099990 DOI: 10.4046/trd.2020.0101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 506 |
Wright C, Ross C, Mc Goldrick N. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)? Evid Based Dent 2020;21:64-5. [PMID: 32591664 DOI: 10.1038/s41432-020-0098-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 507 |
Yang C, Huang Y, Liu S. Therapeutic Development in COVID-19. Adv Exp Med Biol 2021;1318:435-48. [PMID: 33973193 DOI: 10.1007/978-3-030-63761-3_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 508 |
Yao D, Ye H, Huo Z, Wu L, Wei S. Mesenchymal stem cell research progress for the treatment of COVID-19. J Int Med Res. 2020;48:300060520955063. [PMID: 32972277 DOI: 10.1177/0300060520955063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 509 |
Colson P, Lagier JC, Baudoin JP, Bou Khalil J, La Scola B, Raoult D. Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020;39:1601-3. [PMID: 32270412 DOI: 10.1007/s10096-020-03869-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 510 |
Alotaibi M, Ali A, Bakhshwin D, Alatawi Y, Alotaibi S, Alhifany A, Alharthi B, Alharthi N, Alyazidi A, Alharthi Y, Alrafiah A. Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. Int J Gen Med 2021;14:5597-606. [PMID: 34548811 DOI: 10.2147/IJGM.S329881] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 511 |
Wahid B, Amir A, Ameen A, Idrees M. Current status of therapeutic approaches and vaccines for SARS-CoV-2. Future Microbiol 2021. [PMID: 34758638 DOI: 10.2217/fmb-2020-0147] [Reference Citation Analysis]
|
| 512 |
Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020;64. [PMID: 32205349 DOI: 10.1128/aac.00483-20] [Cited by in Crossref: 119] [Cited by in F6Publishing: 89] [Article Influence: 59.5] [Reference Citation Analysis]
|
| 513 |
Mehedi MSA, Tepe JJ. Sc(OTf) 3 -Mediated One-Pot Synthesis of 2,3-Disubstituted Quinolines from Anilines and Epoxides. J Org Chem 2020;85:6741-6. [DOI: 10.1021/acs.joc.0c00803] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 514 |
Israel-Jost V, Coutellec L. [Building the scientific commons. Conflictualities and pluralism in the light of clinical trials Covid-19]. Med Sci (Paris) 2021;37:89-96. [PMID: 33492224 DOI: 10.1051/medsci/2020254] [Reference Citation Analysis]
|
| 515 |
Panovska-Stavridis I, Ridova N, Stojanoska T, Demiri I, Stevanovic M, Stojanovska S, Ristevska T, Dimkovski A, Filipce V, Dimovski A, Grozdanova A. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021). Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2021;42:5-18. [PMID: 33894123 DOI: 10.2478/prilozi-2021-0001] [Reference Citation Analysis]
|
| 516 |
Iyer M, Jayaramayya K, Subramaniam MD, Lee SB, Dayem AA, Cho SG, Vellingiri B. COVID-19: an update on diagnostic and therapeutic approaches. BMB Rep 2020;53:191-205. [PMID: 32336317 [PMID: 32336317 DOI: 10.5483/bmbrep.2020.53.4.080] [Cited by in Crossref: 44] [Article Influence: 22.0] [Reference Citation Analysis]
|
| 517 |
Khodajou-Masouleh H, Shahangian SS, Rasti B. Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. Drug Metab Rev 2021;:1-34. [PMID: 33980089 DOI: 10.1080/03602532.2021.1928686] [Reference Citation Analysis]
|
| 518 |
Jain S, Workman V, Ganeshan R, Obasare ER, Burr A, DeBiasi RM, Freeman JV, Akar J, Lampert R, Rosenfeld LE. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. Heart Rhythm 2020;17:1417-22. [PMID: 32387247 DOI: 10.1016/j.hrthm.2020.04.047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 519 |
Rao GSNK, Gowthami B, Naveen NR, Samudrala PK. An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. Curr Res Pharmacol Drug Discov 2021;2:100063. [PMID: 34870158 DOI: 10.1016/j.crphar.2021.100063] [Reference Citation Analysis]
|
| 520 |
Kifle ZD, Ayele AG, Enyew EF. Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. J Environ Public Health 2021;2021:6631721. [PMID: 33953756 DOI: 10.1155/2021/6631721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 521 |
Alifano M, Alifano P, Forgez P, Iannelli A. Renin-angiotensin system at the heart of COVID-19 pandemic. Biochimie 2020;174:30-3. [PMID: 32305506 DOI: 10.1016/j.biochi.2020.04.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 33.5] [Reference Citation Analysis]
|
| 522 |
Bessalah S, Jebahi S, Mejri N, Salhi I, Khorchani T, Hammadi M. Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). 3 Biotech 2021;11:89. [PMID: 33500874 DOI: 10.1007/s13205-021-02647-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 523 |
Guo W, Pan B, Sakkiah S, Ji Z, Yavas G, Lu Y, Komatsu TE, Lal-Nag M, Tong W, Patterson TA, Hong H. Informing selection of drugs for COVID-19 treatment through adverse events analysis. Sci Rep 2021;11:14022. [PMID: 34234253 DOI: 10.1038/s41598-021-93500-5] [Reference Citation Analysis]
|
| 524 |
Li H, Xue Q, Xu X. Involvement of the Nervous System in SARS-CoV-2 Infection. Neurotox Res 2020;38:1-7. [PMID: 32399719 DOI: 10.1007/s12640-020-00219-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 24.5] [Reference Citation Analysis]
|
| 525 |
Alia E, Grant-Kels JM. Does hydroxychloroquine combat COVID-19? A timeline of evidence. J Am Acad Dermatol 2020;83:e33-4. [PMID: 32283236 DOI: 10.1016/j.jaad.2020.04.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 526 |
Clementi N, Criscuolo E, Diotti RA, Ferrarese R, Castelli M, Dagna L, Burioni R, Clementi M, Mancini N. Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. Front Microbiol 2020;11:1704. [PMID: 32754147 DOI: 10.3389/fmicb.2020.01704] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 527 |
Kashour T, Tleyjeh IM. It is time to drop hydroxychloroquine from our COVID-19 armamentarium. Med Hypotheses 2020;144:110198. [PMID: 33254507 DOI: 10.1016/j.mehy.2020.110198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 528 |
Mehta B, Moezinia CJ, Jannat-Khah D, Gibofsky A, Tornberg H, Pearce-Fisher D, Goodman SM, Salmon JE, Ibrahim S. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists. J Clin Rheumatol 2020;26:224-8. [PMID: 32694358 DOI: 10.1097/RHU.0000000000001539] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 529 |
Sartor Z, Hess B. Increasing the Signal-to-Noise Ratio: COVID-19 Clinical Synopsis for Outpatient Providers. J Prim Care Community Health 2020;11:2150132720922957. [PMID: 32340531 DOI: 10.1177/2150132720922957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 530 |
Yu B, Ke X, Yuan C, Chen P, Zhang Y, Lin N, Yang Y, Wu H. Network Pharmacology Integrated Molecular Docking Reveals the Anti-COVID-19 Mechanism of Xingnaojing Injection. Natural Product Communications 2020;15:1934578X2097802. [DOI: 10.1177/1934578x20978025] [Reference Citation Analysis]
|
| 531 |
Ibrahim MAA, Abdelrahman AHM, Hegazy MF. In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn 2021;39:5756-67. [PMID: 32684114 DOI: 10.1080/07391102.2020.1791958] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 532 |
Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, Stepp HE, Clements TP. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J 2020;287:3633-50. [PMID: 32446285 DOI: 10.1111/febs.15375] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 533 |
Akyıl FT, Karadoğan D, Gürkan CG, Yüksel A, Arıkan H, Eyüboğlu TŞ, Emiralioğlu N, Gürsoy TR, Şerifoğlu İ, Töreyin ZN, Marim F, Kara BY, Özakıncı H, Develi E, Çakmakçı S, Küsbeci TÇ, Karcıoğlu O, Gülhan PY, Erçelik M, Er B, Ataoğlu Ö, Polat D, Kaya İ, Önyılmaz TA, Aydın A, Kızılırmak D, Er AB, Kılınç M, Günaydın FE, Gürz S, Karaoğlanoğlu S, Çelik S, Esendağlı D, Toptay H, Sertçelik ÜÖ, Akgün M. What We Learned about COVID-19 So Far? Notes from Underground. Turk Thorac J 2020;21:185-92. [PMID: 32584236 DOI: 10.5152/TurkThoracJ.2020.20052] [Reference Citation Analysis]
|
| 534 |
Kanimozhi G, Pradhapsingh B, Singh Pawar C, Khan HA, Alrokayan SH, Prasad NR. SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. Front Pharmacol 2021;12:638334. [PMID: 33967772 DOI: 10.3389/fphar.2021.638334] [Reference Citation Analysis]
|
| 535 |
Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, Jain SS, Burkhoff D, Kumaraiah D, Rabbani L, Schwartz A, Uriel N. COVID-19 and Cardiovascular Disease. Circulation. 2020;141:1648-1655. [PMID: 32200663 DOI: 10.1161/circulationaha.120.046941] [Cited by in Crossref: 699] [Cited by in F6Publishing: 444] [Article Influence: 349.5] [Reference Citation Analysis]
|
| 536 |
Negahdaripour M. The Battle Against COVID-19: Where Do We Stand Now? Iran J Med Sci 2020;45:81-2. [PMID: 32210483 DOI: 10.30476/ijms.2020.46357] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
|
| 537 |
Akter R, Rahman MH, Bhattacharya T, Kaushik D, Mittal V, Parashar J, Kumar K, Kabir MT, Tagde P. Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. Environ Sci Pollut Res Int 2021. [PMID: 34664166 DOI: 10.1007/s11356-021-16809-8] [Reference Citation Analysis]
|
| 538 |
Saha BK, Bonnier A, Chong W. Antimalarials as Antivirals for COVID-19: Believe it or Not! Am J Med Sci 2020;360:618-30. [PMID: 32950177 DOI: 10.1016/j.amjms.2020.08.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 539 |
Song P, Li W, Xie J, Hou Y, You C. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta 2020;509:280-7. [PMID: 32531256 DOI: 10.1016/j.cca.2020.06.017] [Cited by in Crossref: 174] [Cited by in F6Publishing: 155] [Article Influence: 87.0] [Reference Citation Analysis]
|
| 540 |
Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, Brocard E, Alhazzani W. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol 2020;123:120-6. [PMID: 32330521 DOI: 10.1016/j.jclinepi.2020.04.016] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 39.0] [Reference Citation Analysis]
|
| 541 |
Rahman MR, Banik A, Chowdhury IM, Sajib EH, Sarkar S. Identification of potential antivirals against SARS-CoV-2 using virtual screening method. Inform Med Unlocked 2021;23:100531. [PMID: 33594342 DOI: 10.1016/j.imu.2021.100531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 542 |
Lythgoe MP, Middleton P. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends Pharmacol Sci 2020;41:363-82. [PMID: 32291112 DOI: 10.1016/j.tips.2020.03.006] [Cited by in Crossref: 191] [Cited by in F6Publishing: 165] [Article Influence: 95.5] [Reference Citation Analysis]
|
| 543 |
Giri A, Das A, Sarkar AK, Giri AK. Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. Genes Environ 2020;42:25. [PMID: 32884603 DOI: 10.1186/s41021-020-00164-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 544 |
Hu N, Pan S, Sun J, Wang Z, Mao H. Mental health treatment online during the COVID-19 outbreak. Eur Arch Psychiatry Clin Neurosci 2020;270:783-4. [PMID: 32361812 DOI: 10.1007/s00406-020-01129-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 545 |
Ahsan W, Alhazmi HA, Patel KS, Mangla B, Al Bratty M, Javed S, Najmi A, Sultan MH, Makeen HA, Khalid A, Mohan S, Taha MME, Sultana S. Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. Front Public Health 2020;8:384. [PMID: 32754570 DOI: 10.3389/fpubh.2020.00384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 546 |
Mian MS, Razaq L, Khan S, Hussain N, Razaq M. Pathological Findings and Management of COVID-19 Patients: A Brief Overview of Modern-day Pandemic. Cureus 2020;12:e8136. [PMID: 32550056 DOI: 10.7759/cureus.8136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 547 |
Nasonov EL. CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS. Naučno-praktičeskaâ revmatologiâ 2020;58:123-32. [DOI: 10.14412/1995-4484-2020-123-132] [Cited by in Crossref: 18] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 548 |
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. [PMID: 32409561 DOI: 10.1136/bmj.m1849] [Cited by in Crossref: 485] [Cited by in F6Publishing: 472] [Article Influence: 242.5] [Reference Citation Analysis]
|
| 549 |
Van Vo G, Bagyinszky E, Park YS, Hulme J, An SSA. SARS-CoV-2 (COVID-19): Beginning to Understand a New Virus. Adv Exp Med Biol 2021;1321:3-19. [PMID: 33656709 DOI: 10.1007/978-3-030-59261-5_1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 550 |
Osuchowski MF, Aletti F, Cavaillon JM, Flohé SB, Giamarellos-Bourboulis EJ, Huber-Lang M, Relja B, Skirecki T, Szabó A, Maegele M. SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. Shock 2020;54:416-37. [PMID: 32433217 DOI: 10.1097/SHK.0000000000001565] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 551 |
Grassin-Delyle S, Salvator H, Brollo M, Catherinot E, Sage E, Couderc LJ, Naline E, Devillier P. Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants. Clin Infect Dis 2020;71:2265-8. [PMID: 32382733 DOI: 10.1093/cid/ciaa546] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 552 |
Alsatli RA. Cardiovascular Complications Related to COVID-19 Disease. Anesth Essays Res 2020;14:359-65. [PMID: 34092842 DOI: 10.4103/aer.AER_105_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 553 |
Ahadian S, Finbloom JA, Mofidfar M, Diltemiz SE, Nasrollahi F, Davoodi E, Hosseini V, Mylonaki I, Sangabathuni S, Montazerian H, Fetah K, Nasiri R, Dokmeci MR, Stevens MM, Desai TA, Khademhosseini A. Micro and nanoscale technologies in oral drug delivery. Adv Drug Deliv Rev 2020;157:37-62. [PMID: 32707147 DOI: 10.1016/j.addr.2020.07.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 554 |
Offerhaus JA, Wilde AAM, Remme CA. Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. Heart Rhythm. 2020;17:1480-1486. [PMID: 32622993 DOI: 10.1016/j.hrthm.2020.07.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 555 |
Yang H, Chi Y, Chen Z, Fan Y, Wu H, Hu X, Wu T, Xiao B, Zhang M. Differential Diagnosis and Hospital Emergency Management for Fastlane Treatment of Central Nervous System Infection Under the COVID-19 Epidemic in Changsha, China. Front Neurol 2020;11:555202. [PMID: 33192989 DOI: 10.3389/fneur.2020.555202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 556 |
Tarek M, Savarino A. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention. Eur J Drug Metab Pharmacokinet 2020;45:715-23. [PMID: 32780273 DOI: 10.1007/s13318-020-00640-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 557 |
Manhas S, Anjali A, Mansoor S, Sharma V, Ahmad A, Rehman MU, Ahmad P. Covid-19 Pandemic and Current Medical Interventions. Arch Med Res 2020;51:473-81. [PMID: 32499154 DOI: 10.1016/j.arcmed.2020.05.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 558 |
Pathak DSK, Salunke DAA, Thivari DP, Pandey A, Nandy DK, Harish V K Ratna D, Pandey DS, Chawla DJ, Mujawar DJ, Dhanwate DA, Menon DV. No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials". Diabetes Metab Syndr 2020;14:1673-80. [PMID: 32905939 DOI: 10.1016/j.dsx.2020.08.033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 559 |
Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Gallant J, Smith LE, Osinusi AO, Brainard DM, Hu H, Phulpin C, Edgar H, Diaz-Cuervo H, Bernardino JI. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. Clin Infect Dis 2020:ciaa1041. [PMID: 32706859 DOI: 10.1093/cid/ciaa1041] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
|
| 560 |
Iftikhar H, Ali HN, Farooq S, Naveed H, Shahzad-Ul-Hussan S. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach. Comput Biol Med 2020;122:103848. [PMID: 32658735 DOI: 10.1016/j.compbiomed.2020.103848] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 561 |
Ibáñez S, Martínez O, Valenzuela F, Silva F, Valenzuela O. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? Clin Rheumatol 2020;39:2461-5. [PMID: 32495226 DOI: 10.1007/s10067-020-05202-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 562 |
Hossain MF, Hasana S, Mamun AA, Uddin MS, Wahed MII, Sarker S, Behl T, Ullah I, Begum Y, Bulbul IJ, Amran MS, Rahman MH, Bin-Jumah MN, Alkahtani S, Mousa SA, Aleya L, Abdel-Daim MM. COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. Front Pharmacol 2020;11:563478. [PMID: 33178016 DOI: 10.3389/fphar.2020.563478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 563 |
Marcia M, Vania B, Pruccoli G, Vallero SG, Barisone E, Scolfaro C, Fagioli F. Acute lymphoblastic leukemia onset in a 3-year-old child with COVID-19. Pediatr Blood Cancer 2020;67:e28423. [PMID: 32706512 DOI: 10.1002/pbc.28423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 564 |
Wang Y, Yang J, Zhuang X, Ling Y, Cao R, Xu Q, Wang P, Xu P, Zhang G. Linking genomic and epidemiologic information to advance the study of COVID-19. Sci Data 2022;9. [DOI: 10.1038/s41597-022-01237-1] [Reference Citation Analysis]
|
| 565 |
Zucchi D, Tani C, Elefante E, Stagnaro C, Carli L, Signorini V, Ferro F, Trentin F, Fulvio G, Cardelli C, Di Battista M, Governato G, Figliomeni A, Mosca M. Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flare. PLoS One 2021;16:e0245274. [PMID: 33439910 DOI: 10.1371/journal.pone.0245274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 566 |
Parperis K. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic. Ann Rheum Dis 2021;80:e8. [PMID: 32321722 DOI: 10.1136/annrheumdis-2020-217557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 567 |
Jirjees F, Saad AK, Al Hano Z, Hatahet T, Al Obaidi H, Dallal Bashi YH. COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic? Infect Dis Rep 2021;13:259-84. [PMID: 33915690 DOI: 10.3390/idr13020029] [Reference Citation Analysis]
|
| 568 |
Kassem DH, Kamal MM. Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis. Front Cell Dev Biol 2020;8:587866. [PMID: 33102489 DOI: 10.3389/fcell.2020.587866] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 569 |
Chitalia VC, Munawar AH. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. J Transl Med 2020;18:390. [PMID: 33059719 DOI: 10.1186/s12967-020-02476-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 570 |
Choudhry N, Zhao X, Xu D, Zanin M, Chen W, Yang Z, Chen J. Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). J Med Chem 2020;63:13205-27. [PMID: 32845145 DOI: 10.1021/acs.jmedchem.0c00626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 571 |
Ait Addi R, Benksim A, Amine M, Cherkaoui M. COVID-19 Outbreak and Perspective in Morocco. Electron J Gen Med 2020;17:em204. [DOI: 10.29333/ejgm/7857] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 572 |
Rahimi F, Talebi Bezmin Abadi A. Ethical and Sensible Dissemination of Information During the COVID-19 Pandemic. Am J Bioeth 2020;20:W4-6. [PMID: 32420828 DOI: 10.1080/15265161.2020.1761200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 573 |
Jegan R, Rajalakshmy P, Subha Hency Jose P, Nimi WS. 2019-nCoV effects, transmission and preventive measures: an overview. Z Gesundh Wiss 2021;:1-9. [PMID: 33432288 DOI: 10.1007/s10389-020-01435-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 574 |
Costamagna G, Abati E, Bresolin N, Comi GP, Corti S. Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. J Neurol 2021;268:1580-91. [PMID: 32804279 DOI: 10.1007/s00415-020-10149-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 575 |
Alimardani V, Abolmaali SS, Tamaddon AM, Singh BP. Recent Advances on Nanotechnology-Based Strategies for Prevention, Diagnosis, and Treatment of Coronavirus Infections. Journal of Nanomaterials 2021;2021:1-20. [DOI: 10.1155/2021/9495126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 576 |
Chandler LC, Yusuf IH, McClements ME, Barnard AR, MacLaren RE, Xue K. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. Int J Mol Sci 2020;21:E4972. [PMID: 32674481 DOI: 10.3390/ijms21144972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 577 |
Kumar R, Gupta N, Kodan P, Mittal A, Soneja M, Wig N. Battling COVID-19: using old weapons for a new enemy. Trop Dis Travel Med Vaccines 2020;6:6. [PMID: 32454984 DOI: 10.1186/s40794-020-00107-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 578 |
Peng F, Tu L, Yang Y, Hu P, Wang R, Hu Q, Cao F, Jiang T, Sun J, Xu G, Chang C. Management and Treatment of COVID-19: The Chinese Experience. Can J Cardiol 2020;36:915-30. [PMID: 32439306 DOI: 10.1016/j.cjca.2020.04.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 35.0] [Reference Citation Analysis]
|
| 579 |
Sultan S, Acharya Y. Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. Vascular 2021;29:220-7. [PMID: 32691699 DOI: 10.1177/1708538120941635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 580 |
Sturrock BR, Chevassut TJ. Chloroquine and COVID-19 - a potential game changer? Clin Med (Lond) 2020:clinmed. [PMID: 32303497 DOI: 10.7861/clinmed.2020-0129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 581 |
Belghmaidi S, Nassih H, Boutgayout S, El Fakiri K, El Qadiry R, Hajji I, Bourrahouate A, Moutaouakil A. Third Cranial Nerve Palsy Presenting with Unilateral Diplopia and Strabismus in a 24-Year-Old Woman with COVID-19. Am J Case Rep 2020;21:e925897. [PMID: 33056942 DOI: 10.12659/AJCR.925897] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 582 |
Guvenmez O, Keskin H, Ay B, Birinci S, Kanca MF. The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study. J Popul Ther Clin Pharmacol 2020;27:e5-e10. [PMID: 32543164 DOI: 10.15586/jptcp.v27iSP1.684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 583 |
Cohen IV, Makunts T, Moumedjian T, Issa MA, Abagyan R. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. Sci Rep 2020;10:19199. [PMID: 33154498 DOI: 10.1038/s41598-020-76258-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 584 |
Reshad RAI, Riana SH, Chowdhury MA, Moin AT, Miah F, Sarkar B, Jewel NA. Diabetes in COVID-19 patients: challenges and possible management strategies. Egypt J Bronchol 2021;15. [DOI: 10.1186/s43168-021-00099-2] [Reference Citation Analysis]
|
| 585 |
Klimke A, Hefner G, Will B, Voss U. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. Med Hypotheses 2020;142:109783. [PMID: 32402766 DOI: 10.1016/j.mehy.2020.109783] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 586 |
Addeo A, Obeid M, Friedlaender A. COVID-19 and lung cancer: risks, mechanisms and treatment interactions. J Immunother Cancer 2020;8:e000892. [PMID: 32434788 DOI: 10.1136/jitc-2020-000892] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 587 |
Kumar N, Sarma H, Sastry GN. Repurposing of approved drug molecules for viral infectious diseases: a molecular modelling approach. J Biomol Struct Dyn 2021;:1-17. [PMID: 33810775 DOI: 10.1080/07391102.2021.1905558] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 588 |
[DOI: 10.1101/2020.03.03.20030353] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
|
| 589 |
Lei Z, Cao H, Jie Y, Huang Z, Guo X, Chen J, Peng L, Cao H, Dai X, Liu J, Li X, Zhu J, Xu W, Chen D, Gao Z, He JR, Lin BL. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. Travel Med Infect Dis 2020;35:101664. [PMID: 32278758 DOI: 10.1016/j.tmaid.2020.101664] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 590 |
Ippolito MM, Flexner C. Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter? Clin Infect Dis 2020;71:2965-7. [PMID: 32474576 DOI: 10.1093/cid/ciaa691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 591 |
Dziedzic A, Wojtyczka R. The impact of coronavirus infectious disease 19 (COVID-19) on oral health. Oral Dis 2021;27 Suppl 3:703-6. [PMID: 32304276 DOI: 10.1111/odi.13359] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 592 |
Ezhilan M, Suresh I, Nesakumar N. SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge. Measurement (Lond) 2021;168:108335. [PMID: 33519010 DOI: 10.1016/j.measurement.2020.108335] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 593 |
Sadio AJ, Gbeasor-Komlanvi FA, Konu RY, Bakoubayi AW, Tchankoni MK, Bitty-Anderson AM, Gomez IM, Denadou CP, Anani J, Kouanfack HR, Kpeto IK, Salou M, Ekouevi DK. Assessment of self-medication practices in the context of the COVID-19 outbreak in Togo. BMC Public Health 2021;21:58. [PMID: 33407321 DOI: 10.1186/s12889-020-10145-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 594 |
Rastogi A, Padhi A, Syed S, Keshan P, Gupta E. Mapping the footprints of COVID-19 pandemic. J Family Med Prim Care 2021;10:2467-76. [PMID: 34568121 DOI: 10.4103/jfmpc.jfmpc_2361_20] [Reference Citation Analysis]
|
| 595 |
Carrière F, Longhi S, Record M. The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. Biochimie 2020;179:237-46. [PMID: 32485205 DOI: 10.1016/j.biochi.2020.05.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 596 |
Prommer E. Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. Am J Hosp Palliat Care 2021;38:480-8. [PMID: 32929975 DOI: 10.1177/1049909120952773] [Reference Citation Analysis]
|
| 597 |
Islam H, Rahman A, Masud J, Shweta DS, Araf Y, Ullah MA, Sium SMA, Sarkar B. A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand? Electron J Gen Med 2020;17:em251. [DOI: 10.29333/ejgm/8258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 598 |
Ali AS, Ibrahim IM, Burzangi AS, Ghoneim RH, Aljohani HS, Alsamhan HA, Barakat J. Scoping insight on antiviral drugs against COVID-19. Arab J Chem 2021;14:103385. [PMID: 34909060 DOI: 10.1016/j.arabjc.2021.103385] [Reference Citation Analysis]
|
| 599 |
Robinson CP, Busl KM. Neurologic Manifestations of Severe Respiratory Viral Contagions. Crit Care Explor 2020;2:e0107. [PMID: 32426749 DOI: 10.1097/CCE.0000000000000107] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 600 |
Kashour Z, Riaz M, Garbati MA, AlDosary O, Tlayjeh H, Gerberi D, Murad MH, Sohail MR, Kashour T, Tleyjeh IM. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. J Antimicrob Chemother 2021;76:30-42. [PMID: 33031488 DOI: 10.1093/jac/dkaa403] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 20.5] [Reference Citation Analysis]
|
| 601 |
Monti M, Vertogen B, Masini C, Donati C, Lilli C, Zingaretti C, Musuraca G, De Giorgi U, Cerchione C, Farolfi A, Cortesi P, Viale P, Martinelli G, Nanni O. Hydroxychloroquine as Prophylaxis for COVID-19: A Review. Front Pharmacol 2020;11:605185. [PMID: 33343376 DOI: 10.3389/fphar.2020.605185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 602 |
Faraz N, Khan Y, Goufo EFD, Anjum A, Anjum A. Dynamic analysis of the mathematical model of COVID-19 with demographic effects. Z Naturforsch C J Biosci 2020;75:389-96. [PMID: 32920544 DOI: 10.1515/znc-2020-0121] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 603 |
Cheke RS, Shinde S, Ambhore J, Adhao V, Cheke D. Coronavirus: Hotspot on coronavirus disease 2019 in India. IJMS 2020;72:29-34. [DOI: 10.25259/ijms_33_2020] [Cited by in Crossref: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 604 |
Dubey AK, Singh A, Prakash S, Kumar M, Singh AK. Race to arsenal COVID-19 therapeutics: Current alarming status and future directions. Chem Biol Interact 2020;332:109298. [PMID: 33121920 DOI: 10.1016/j.cbi.2020.109298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 605 |
Kumaravel SK, Subramani RK, Jayaraj Sivakumar TK, Madurai Elavarasan R, Manavalanagar Vetrichelvan A, Annam A, Subramaniam U. Investigation on the impacts of COVID-19 quarantine on society and environment: Preventive measures and supportive technologies. 3 Biotech 2020;10:393. [PMID: 32821645 DOI: 10.1007/s13205-020-02382-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 606 |
Al Khoury C, Bashir Z, Tokajian S, Nemer N, Merhi G, Nemer G. In silico evidence of beauvericin antiviral activity against SARS-CoV-2. Comput Biol Med 2021;141:105171. [PMID: 34968860 DOI: 10.1016/j.compbiomed.2021.105171] [Reference Citation Analysis]
|
| 607 |
Marraha F, Al Faker I, Gallouj S. A Review of the Dermatological Manifestations of Coronavirus Disease 2019 (COVID-19). Dermatol Res Pract 2020;2020:9360476. [PMID: 32849867 DOI: 10.1155/2020/9360476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 608 |
Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res 2021;197:105212. [PMID: 34838583 DOI: 10.1016/j.antiviral.2021.105212] [Reference Citation Analysis]
|
| 609 |
Wang M, Zhang L, Li Q, Wang B, Liang Z, Sun Y, Nie J, Wu J, Su X, Qu X, Li Y, Wang Y, Huang W. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Emerg Microbes Infect 2022;11:18-29. [PMID: 34818119 DOI: 10.1080/22221751.2021.2008775] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 610 |
Delgado-Gonzalez P, Gonzalez-Villarreal CA, Roacho-Perez JA, Quiroz-Reyes AG, Islas JF, Delgado-Gallegos JL, Arellanos-Soto D, Galan-Huerta KA, Garza-Treviño EN. Inflammatory effect on the gastrointestinal system associated with COVID-19. World J Gastroenterol 2021; 27(26): 4160-4171 [PMID: 34326616 DOI: 10.3748/wjg.v27.i26.4160] [Reference Citation Analysis]
|
| 611 |
Rahimi Pordanjani S, Hasanpour A, Askarpour H, Bastam D, Rafiee M, Khazaei Z, Mazaheri E, Vaziri MH, Sabour S. Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of COVID-19 Pandemic: A Narrative Review. Int J Prev Med 2021;12:38. [PMID: 34249287 DOI: 10.4103/ijpvm.IJPVM_469_20] [Reference Citation Analysis]
|
| 612 |
Jarab AS, Al-Qerem W, Mukattash TL, Al-Hajjeh DM. Pharmacy and Pharm.D students' knowledge and information needs about COVID-19. Int J Clin Pract 2021;75:e13696. [PMID: 32891073 DOI: 10.1111/ijcp.13696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 613 |
Silva TF, Tomiotto-Pellissier F, Sanfelice RA, Gonçalves MD, da Silva Bortoleti BT, Detoni MB, Rodrigues ACJ, Carloto ACM, Concato VM, Siqueira EDS, Costa IN, Pavanelli WR, Conchon-Costa I, Miranda-Sapla MM. A 21st Century Evil: Immunopathology and New Therapies of COVID-19. Front Immunol 2020;11:562264. [PMID: 33193331 DOI: 10.3389/fimmu.2020.562264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 614 |
Dourmishev L, Guleva D, Pozharashka J, Drenovska K, Miteva L, Vassileva S. Autoimmune connective tissue diseases in the COVID-19 pandemic. Clin Dermatol 2021;39:56-63. [PMID: 33972054 DOI: 10.1016/j.clindermatol.2020.12.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 615 |
Hecel A, Ostrowska M, Stokowa-Sołtys K, Wątły J, Dudek D, Miller A, Potocki S, Matera-Witkiewicz A, Dominguez-Martin A, Kozłowski H, Rowińska-Żyrek M. Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against COVID-19? Pharmaceuticals (Basel) 2020;13:E228. [PMID: 32882888 DOI: 10.3390/ph13090228] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 616 |
Benbouguerra K, Chafai N, Chafaa S, Touahria YI, Tlidjane H. New α-Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease. J Mol Struct 2021;1239:130480. [PMID: 33903777 DOI: 10.1016/j.molstruc.2021.130480] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 617 |
Elhusseiny KM, Abd-Elhay FA, Kamel MG. Possible therapeutic agents for COVID-19: a comprehensive review. Expert Rev Anti Infect Ther 2020;18:1005-20. [PMID: 32538209 DOI: 10.1080/14787210.2020.1782742] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 618 |
Awasthi A, Vishwas S, Corrie L, Kumar R, Khursheed R, Kaur J, Kumar R, Arya KR, Gulati M, Kumar B, Singh SK, Pandey NK, Wadhwa S, Kumar P, Kapoor B, Gupta RK, Kumar A. OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. Eur J Pharmacol 2020;884:173381. [PMID: 32721449 DOI: 10.1016/j.ejphar.2020.173381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 619 |
Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, Makhawi AM. Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach. Biomed Res Int 2020;2020:2683286. [PMID: 32461973 DOI: 10.1155/2020/2683286] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 620 |
Cassone A, Iacoviello L, Cauda R. Knowing more about chloroquine/hydroxycloroquine in COVID-19 patients. Future Microbiol 2020;15:1523-6. [PMID: 33206554 DOI: 10.2217/fmb-2020-0247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 621 |
Fiscon G, Conte F, Farina L, Paci P. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. PLoS Comput Biol 2021;17:e1008686. [PMID: 33544720 DOI: 10.1371/journal.pcbi.1008686] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 622 |
Aghamollaei H, Sarvestani R, Bakherad H, Zare H, Guest PC, Ranjbar R, Sahebkar A. Emerging Technologies for the Treatment of COVID-19. Adv Exp Med Biol 2021;1321:81-96. [PMID: 33656715 DOI: 10.1007/978-3-030-59261-5_7] [Reference Citation Analysis]
|
| 623 |
Kumar R, Al-Turjman F, Srinivas LNB, Braveen M, Ramakrishnan J. ANFIS for prediction of epidemic peak and infected cases for COVID-19 in India. Neural Comput Appl 2021;:1-14. [PMID: 34566264 DOI: 10.1007/s00521-021-06412-w] [Reference Citation Analysis]
|
| 624 |
Farhoudian A, Baldacchino A, Clark N, Gerra G, Ekhtiari H, Dom G, Mokri A, Sadeghi M, Nematollahi P, Demasi M, Schütz CG, Hash-Emian SM, Tabarsi P, Galea-Singer S, Carrà G, Clausen T, Kouimtsidis C, Tolomeo S, Radfar SR, Razaghi EM. COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper. Basic Clin Neurosci 2020;11:133-50. [PMID: 32855772 DOI: 10.32598/bcn.11.covid19.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 625 |
Brizneda MV, Bansal A, Jain V, Kapadia S, Svensson LG, Menon V, Cremer P, Reed G, Rampersad P, Grimm R, Griffin BP, Xu B. Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications. Cardiovasc Diagn Ther 2021;11:939-53. [PMID: 34295715 DOI: 10.21037/cdt-20-779] [Reference Citation Analysis]
|
| 626 |
Rayner PJ, Gillions JP, Hannibal VD, John RO, Duckett SB. Hyperpolarisation of weakly binding N-heterocycles using signal amplification by reversible exchange. Chem Sci 2021;12:5910-7. [PMID: 34168816 DOI: 10.1039/d0sc06907h] [Reference Citation Analysis]
|
| 627 |
Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med 2020;8:539-41. [PMID: 32304640 DOI: 10.1016/S2213-2600(20)30172-7] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 38.5] [Reference Citation Analysis]
|
| 628 |
Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect Public Health 2020;13:1405-14. [PMID: 32684351 DOI: 10.1016/j.jiph.2020.07.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 629 |
Sallard E, Belhadi D, Lescure FX, Yazdanpanah Y, Peiffer-Smadja N. Clinical trial protocols of repurposed prophylaxis for COVID-19: A review. Infect Dis Now 2021;51:7-13. [PMID: 33022293 DOI: 10.1016/j.medmal.2020.09.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 630 |
Zhong H, Wang Y, Zhang ZL, Liu YX, Le KJ, Cui M, Yu YT, Gu ZC, Gao Y, Lin HW. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. Pharmacol Res. 2020;157:104872. [PMID: 32360583 DOI: 10.1016/j.phrs.2020.104872] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 19.0] [Reference Citation Analysis]
|
| 631 |
Santos IA, Grosche VR, Bergamini FRG, Sabino-Silva R, Jardim ACG. Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment? Front Microbiol 2020;11:1818. [PMID: 32903349 DOI: 10.3389/fmicb.2020.01818] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 632 |
Shi YJ, Wang H. Progress in the diagnosis and treatment of COVID-19 and the role of surgeons in the front line of the pandemic. Surg Today 2020;50:1544-8. [PMID: 32886210 DOI: 10.1007/s00595-020-02090-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 633 |
Al-Quteimat OM MSc, BCOP, Amer AM R.Ph, MSc. SARS-CoV-2 outbreak: How can pharmacists help? Res Social Adm Pharm 2021;17:480-2. [PMID: 32241695 DOI: 10.1016/j.sapharm.2020.03.018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 634 |
Jing R, Vunnam RR, Yang Y, Karevoll A, Vunnam SR. Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection. J Pure Appl Microbiol 2020;14:733-40. [DOI: 10.22207/jpam.14.spl1.10] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 635 |
Kotta S, Aldawsari HM, Badr-Eldin SM, Alhakamy NA, Md S, Nair AB, Deb PK. Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. Front Mol Biosci 2020;7:606393. [PMID: 33282914 DOI: 10.3389/fmolb.2020.606393] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 636 |
Cassidy C, Dever D, Stanbery L, Edelman G, Dworkin L, Nemunaitis J. FDA efficiency for approval process of COVID-19 therapeutics. Infect Agent Cancer 2020;15:73. [PMID: 33292374 DOI: 10.1186/s13027-020-00338-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 637 |
Fernandes ACL, Vale AJM, Guzen FP, Pinheiro FI, Cobucci RN, de Azevedo EP. Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. Front Med (Lausanne) 2020;7:546. [PMID: 33043030 DOI: 10.3389/fmed.2020.00546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 638 |
Fan Y, Guo T, Lu Z. Myocardial Injury in COVID-19-Can We Successfully Target Inflammation?-Reply. JAMA Cardiol 2020;5:1070-1. [PMID: 32936268 DOI: 10.1001/jamacardio.2020.2572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 639 |
Tang LY, Wang J. Anesthesia and COVID-19: What We Should Know and What We Should Do. Semin Cardiothorac Vasc Anesth 2020;24:127-37. [PMID: 32336243 DOI: 10.1177/1089253220921590] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 640 |
Chang CK, Lin SM, Satange R, Lin SC, Sun SC, Wu HY, Kehn-Hall K, Hou MH. Targeting protein-protein interaction interfaces in COVID-19 drug discovery. Comput Struct Biotechnol J 2021;19:2246-55. [PMID: 33936565 DOI: 10.1016/j.csbj.2021.04.003] [Reference Citation Analysis]
|
| 641 |
Elshabrawy HA. SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. Vaccines (Basel) 2020;8:E335. [PMID: 32585913 DOI: 10.3390/vaccines8020335] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 642 |
Roomi S, Ullah W, Ahmed F, Farooq S, Sadiq U, Chohan A, Jafar M, Saddique M, Khanal S, Watson R, Boigon M. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. J Med Internet Res 2020;22:e21758. [PMID: 32784192 DOI: 10.2196/21758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 643 |
Jukič M, Janežič D, Bren U. Potential Novel Thioether-Amide or Guanidine-Linker Class of SARS-CoV-2 Virus RNA-Dependent RNA Polymerase Inhibitors Identified by High-Throughput Virtual Screening Coupled to Free-Energy Calculations. Int J Mol Sci 2021;22:11143. [PMID: 34681802 DOI: 10.3390/ijms222011143] [Reference Citation Analysis]
|
| 644 |
Li R, Hu S, Chen P, Jiang J, Cui G, Wang DW. Saving critically ill COVID-19 patients with mechanical circulatory support. Ann Transl Med 2021;9:1221. [PMID: 34532358 DOI: 10.21037/atm-20-5169] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 645 |
Baralić K, Jorgovanović D, Živančević K, Antonijević Miljaković E, Antonijević B, Buha Djordjevic A, Ćurčić M, Đukić-Ćosić D. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. Toxicol Appl Pharmacol 2020;406:115237. [PMID: 32920000 DOI: 10.1016/j.taap.2020.115237] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 646 |
Xinias I, Mavroudi A, Kirvassilis F, Antachopoulos C, Roilides E. Covid-19: Face Mask Protection in the Pediatric Setting. Maedica (Bucur) 2021;16:149-51. [PMID: 34221172 DOI: 10.26574/maedica.2020.16.1.149] [Reference Citation Analysis]
|
| 647 |
Sen D, Bhaumik S, Debnath P, Debnath S. Potentiality of Moringa oleifera against SARS-CoV-2: identified by a rational computer aided drug design method. J Biomol Struct Dyn 2021;:1-18. [PMID: 33719855 DOI: 10.1080/07391102.2021.1898475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 648 |
Shi J, Xiao Y, Zhang Y, Geng D, Cong D, Shi KX, Knapp RJ. Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. Br J Clin Pharmacol 2021;87:2170-85. [PMID: 33119136 DOI: 10.1111/bcp.14629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 649 |
Oleribe OO, Oskouipour P, Nwanyanwu O, Taylor-Robinson SD. The COVID-19 era: the view from Nigeria. QJM 2021;114:13-5. [PMID: 33118021 DOI: 10.1093/qjmed/hcaa297] [Reference Citation Analysis]
|
| 650 |
Mohan B, Choudhary M. Synthesis, crystal structure, computational study and anti-virus effect of mixed ligand copper (II) complex with ONS donor Schiff base and 1, 10-phenanthroline. J Mol Struct 2021;1246:131246. [PMID: 34658419 DOI: 10.1016/j.molstruc.2021.131246] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 651 |
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55:105932. [PMID: 32145363 DOI: 10.1016/j.ijantimicag.2020.105932] [Cited by in Crossref: 466] [Cited by in F6Publishing: 387] [Article Influence: 233.0] [Reference Citation Analysis]
|
| 652 |
Valentini M, Zmerly H. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept. J Popul Ther Clin Pharmacol 2020;27:e14-25. [PMID: 32650355 DOI: 10.15586/jptcp.v27iSP1.689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 653 |
Stawicki SP, Jeanmonod R, Miller AC, Paladino L, Gaieski DF, Yaffee AQ, De Wulf A, Grover J, Papadimos TJ, Bloem C, Galwankar SC, Chauhan V, Firstenberg MS, Di Somma S, Jeanmonod D, Garg SM, Tucci V, Anderson HL, Fatimah L, Worlton TJ, Dubhashi SP, Glaze KS, Sinha S, Opara IN, Yellapu V, Kelkar D, El-Menyar A, Krishnan V, Venkataramanaiah S, Leyfman Y, Saoud Al Thani HA, Wb Nanayakkara P, Nanda S, Cioè-Peña E, Sardesai I, Chandra S, Munasinghe A, Dutta V, Dal Ponte ST, Izurieta R, Asensio JA, Garg M. The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper. J Glob Infect Dis 2020;12:47-93. [PMID: 32773996 DOI: 10.4103/jgid.jgid_86_20] [Cited by in Crossref: 103] [Cited by in F6Publishing: 84] [Article Influence: 51.5] [Reference Citation Analysis]
|
| 654 |
Ghaebi M, Osali A, Valizadeh H, Roshangar L, Ahmadi M. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances. J Cell Physiol 2020;235:9098-109. [PMID: 32557648 DOI: 10.1002/jcp.29771] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 655 |
Ingraham NE, Tignanelli CJ. Fact Versus Science Fiction: Fighting Coronavirus Disease 2019 Requires the Wisdom to Know the Difference. Crit Care Explor 2020;2:e0108. [PMID: 32426750 DOI: 10.1097/CCE.0000000000000108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 656 |
Mir JM, Khan MW, Shalla AH, Maurya RC. A Nonclinical Spectroscopic Approach for Diagnosing Covid-19: A Concise Perspective. J Appl Spectrosc 2021;:1-7. [PMID: 34538886 DOI: 10.1007/s10812-021-01238-9] [Reference Citation Analysis]
|
| 657 |
Chen B, Liu M, Huang C. Current diagnostic and therapeutic strategies for COVID-19. J Pharm Anal 2021;11:129-37. [PMID: 33520327 DOI: 10.1016/j.jpha.2020.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 658 |
Spadera L, Spadera M. Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV. Med Hypotheses 2020;144:110293. [PMID: 33254486 DOI: 10.1016/j.mehy.2020.110293] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 659 |
Komissarov A, Molodtsov I, Ivanova O, Maryukhnich E, Kudryavtseva S, Mazus A, Nikonov E, Vasilieva E. High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. PLoS One 2021;16:e0246396. [PMID: 33513195 DOI: 10.1371/journal.pone.0246396] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 660 |
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;105938. [PMID: 32171740 DOI: 10.1016/j.ijantimicag.2020.105938] [Cited by in Crossref: 503] [Cited by in F6Publishing: 457] [Article Influence: 251.5] [Reference Citation Analysis]
|
| 661 |
Shagufta, Ahmad I. An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity. ChemistrySelect 2021;6:11502-27. [PMID: 34909460 DOI: 10.1002/slct.202103301] [Reference Citation Analysis]
|
| 662 |
Schijns V, Lavelle EC. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Eur J Immunol 2020;50:932-8. [PMID: 32438473 DOI: 10.1002/eji.202048693] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 663 |
Sisti G, Schiattarella A, Sisti A. Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report. Acta Biomed 2020;91:e2020123. [PMID: 33525254 DOI: 10.23750/abm.v91i4.10216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 664 |
Al-Bari AA. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. Curr Drug Targets 2020;21:1703-21. [PMID: 32552642 DOI: 10.2174/1389450121666200617133142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 665 |
Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, Scher JU, Guttmann A, Carlucci PM, Deonaraine KK, Golpanian M, Robins K, Chang M, Belmont HM, Buyon JP, Blazer AD, Saxena A, Izmirly PM; NYU WARCOV Investigators. Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol 2020;72:1971-80. [PMID: 32715660 DOI: 10.1002/art.41450] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 666 |
Joshi G, Thakur S, Mayank, Poduri R. Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. Food Chem Toxicol 2021;151:112106. [PMID: 33722600 DOI: 10.1016/j.fct.2021.112106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 667 |
Al-Quteimat OM, Amer AM. The Impact of the COVID-19 Pandemic on Cancer Patients. Am J Clin Oncol. 2020;43:452-455. [PMID: 32304435 DOI: 10.1097/coc.0000000000000712] [Cited by in Crossref: 83] [Cited by in F6Publishing: 54] [Article Influence: 41.5] [Reference Citation Analysis]
|
| 668 |
De P, Chakraborty I, Karna B, Mazumder N. Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. Eur J Pharmacol 2021;898:173977. [PMID: 33639193 DOI: 10.1016/j.ejphar.2021.173977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 669 |
Sandhu T, Tieng A, Chilimuri S, Franchin G. A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. Can J Infect Dis Med Microbiol 2020;2020:8865954. [PMID: 33133323 DOI: 10.1155/2020/8865954] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 670 |
Mishra A, Rathore AS. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2. Mol Divers 2022. [PMID: 35000060 DOI: 10.1007/s11030-021-10358-5] [Reference Citation Analysis]
|
| 671 |
Granados-Montiel J, Hazan-Lasri E, Franco-Cendejas R, Chávez-Heres T, Silva-Bermudez P, Aguilar-Gaytán R, Manzano-León N, Méndez-Maldonado K, Alvarez-Arce A, Martínez-Portilla RJ. New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial). BMJ Open 2021;11:e045190. [PMID: 34344672 DOI: 10.1136/bmjopen-2020-045190] [Reference Citation Analysis]
|
| 672 |
Ghareeb DA, Saleh SR, Nofal MS, Kaddah MMY, Hassan SF, Seif IK, El-Zahaby SA, Khedr SM, Kenawy MY, Masoud AA, Soudi SA, Sobhy AA, Sery JG, El-Wahab MGA, Elmoneam AAA, Al-Mahallawi AM, El-Demellawy MA. Potential therapeutic and pharmacological strategies for SARS-CoV2. J Pharm Investig 2021;:1-16. [PMID: 33688448 DOI: 10.1007/s40005-021-00520-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 673 |
Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. Am J Emerg Med. 2020;. [PMID: 32336586 DOI: 10.1016/j.ajem.2020.04.035] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 674 |
Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta Pharmacol Sin 2020;41:1377-86. [PMID: 32968208 DOI: 10.1038/s41401-020-00519-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 675 |
Timerbulatov SV, Timerbulstov MV, Gainullina EN, Gafarova AR, Timerbulatov VM. [Drug treatment of coronavirus disease COVID-19: evidence exists?]. Khirurgiia (Mosk) 2020;:90-7. [PMID: 32573538 DOI: 10.17116/hirurgia202006190] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 676 |
Battineni G, Chintalapudi N, Amenta F. SARS-CoV-2 epidemic calculation in Italy by SEIR compartmental models. ACI 2020. [DOI: 10.1108/aci-09-2020-0060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 677 |
Valle C, Martin B, Touret F, Shannon A, Canard B, Guillemot JC, Coutard B, Decroly E. Drugs against SARS-CoV-2: What do we know about their mode of action? Rev Med Virol 2020;30:1-10. [PMID: 32779326 DOI: 10.1002/rmv.2143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 678 |
Choupoo NS, Das SK, Haldar R, Sarkar H, Tewari R, Ray S. Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. Indian J Crit Care Med 2020;24:1106-13. [PMID: 33384519 DOI: 10.5005/jp-journals-10071-23664] [Reference Citation Analysis]
|
| 679 |
Anikwe CC, Ogah CO, Anikwe IH, Okorochukwu BC, Ikeoha CC. Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. Int J Gynaecol Obstet 2020;151:197-202. [PMID: 32608513 DOI: 10.1002/ijgo.13293] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 680 |
Kestelyn E, Dung NTP, Lam Minh Y, Hung LM, Quan NM, Dung NT, Minh NNQ, Xuan TC, Phong NT, Ninh Thi Thanh V, Donovan J, Tu TNH, Nhat LTH, Truong NT, Man DNH, Thao HP, Ngoc NM, Lam VT, Phat HH, Phuong PM, Geskus RB, Ha VTN, Quang NN, Tran Tinh H, Tan LV, Thwaites GE, Day JN, Chau NVV; OUCRU COVID-19 Research Group. A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome Open Res 2020;5:141. [PMID: 33110944 DOI: 10.12688/wellcomeopenres.15936.1] [Reference Citation Analysis]
|
| 681 |
Rahimi H, Allahyari A, Ataei Azimi S, Kamandi M, Mozaheb Z, Zemorshidi F, Khadem-Rezaiyan M, Bary A, Seddigh-Shamsi M, Nodeh MM. Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: study protocol for a randomized controlled trial. Trials 2021;22:349. [PMID: 34011413 DOI: 10.1186/s13063-021-05292-8] [Reference Citation Analysis]
|
| 682 |
Penman SL, Kiy RT, Jensen RL, Beoku-Betts C, Alfirevic A, Back D, Khoo SH, Owen A, Pirmohamed M, Park BK, Meng X, Goldring CE, Chadwick AE. Safety perspectives on presently considered drugs for the treatment of COVID-19. Br J Pharmacol 2020;177:4353-74. [PMID: 32681537 DOI: 10.1111/bph.15204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 683 |
Dale CR, Starcher RW, Chang SC, Robicsek A, Parsons G, Goldman JD, Vovan A, Hotchkin D, Gluckman TJ. Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study. Crit Care 2021;25:70. [PMID: 33596975 DOI: 10.1186/s13054-021-03504-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 684 |
Skariyachan S, Gopal D, Chakrabarti S, Kempanna P, Uttarkar A, Muddebihalkar AG, Niranjan V. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs. Comput Biol Med 2020;126:104054. [PMID: 33074111 DOI: 10.1016/j.compbiomed.2020.104054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 685 |
Ayukekbong JA, Ntemgwa ML, Ayukekbong SA, Ashu EE, Agbor TA. COVID-19 compared to other epidemic coronavirus diseases and the flu. World J Clin Infect Dis 2020; 10(1): 1-13 [DOI: 10.5495/wjcid.v10.i1.1] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 686 |
Seffer MT, Martens-Lobenhoffer J, Schmidt JJ, Eden G, Bode-Böger SM, Kielstein JT. Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter -a device approved for the treatment of COVID-19 patients. Ther Apher Dial 2021;25:237-41. [PMID: 32558210 DOI: 10.1111/1744-9987.13549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 687 |
Rein T. Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts. J Cell Biochem 2021. [PMID: 34668225 DOI: 10.1002/jcb.30166] [Reference Citation Analysis]
|
| 688 |
Bensalah N, Midassi S, Ahmad MI, Bedoui A. Degradation of hydroxychloroquine by electrochemical advanced oxidation processes. Chem Eng J 2020;402:126279. [PMID: 32834760 DOI: 10.1016/j.cej.2020.126279] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 689 |
Faheem, Kumar BK, Sekhar KVGC, Kunjiappan S, Jamalis J, Balaña-Fouce R, Tekwani BL, Sankaranarayanan M. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Bioorg Chem 2020;104:104269. [PMID: 32947136 DOI: 10.1016/j.bioorg.2020.104269] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 690 |
Zhang N, Li C, Hu Y, Li K, Liang J, Wang L, Du L, Jiang S. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect 2020;22:231-5. [PMID: 32387332 DOI: 10.1016/j.micinf.2020.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 691 |
Verma N, Patel D, Pandya A. Emerging diagnostic tools for detection of COVID-19 and perspective. Biomed Microdevices 2020;22:83. [PMID: 33230627 DOI: 10.1007/s10544-020-00534-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 692 |
Rauf A, Abu-Izneid T, Olatunde A, Ahmed Khalil A, Alhumaydhi FA, Tufail T, Shariati MA, Rebezov M, Almarhoon ZM, Mabkhot YN, Alsayari A, Rengasamy KRR. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int J Environ Res Public Health 2020;17:E8155. [PMID: 33158234 DOI: 10.3390/ijerph17218155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 693 |
Bailly C, Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol Ther. 2020;214:107618. [PMID: 32592716 DOI: 10.1016/j.pharmthera.2020.107618] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 29.0] [Reference Citation Analysis]
|
| 694 |
Çokuğraş H, Önal P. SARS-CoV-2 infection in children. Turk Pediatri Ars 2020;55:95-102. [PMID: 32684754 DOI: 10.14744/TurkPediatriArs.2020.20270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 695 |
Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, Chatham W, Cohen S, Costenbader K, Gravallese EM, Kalil AC, Weinblatt ME, Winthrop K, Mudano AS, Turner A, Saag KG. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol 2020;72:e1-e12. [PMID: 32734689 DOI: 10.1002/art.41437] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 696 |
Ng TSB, Leblanc K, Yeung DF, Tsang TSM. Medication use during COVID-19: Review of recent evidence. Can Fam Physician 2021;67:171-9. [PMID: 33727376 DOI: 10.46747/cfp.6703171] [Reference Citation Analysis]
|
| 697 |
Ledford H. Chloroquine hype is derailing the search for coronavirus treatments. Nature 2020;580:573. [PMID: 32332911 DOI: 10.1038/d41586-020-01165-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 698 |
McIntyre KM, Favre NM, Kuo CC, Carr MM. Systematic Review of Sensorineural Hearing Loss Associated With COVID-19 Infection. Cureus 2021;13:e19757. [PMID: 34938632 DOI: 10.7759/cureus.19757] [Reference Citation Analysis]
|
| 699 |
Holzhauser L, Lourenco L, Sarswat N, Kim G, Chung B, Nguyen AB. Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options. Am J Transplant 2020;20:2916-22. [PMID: 32378314 DOI: 10.1111/ajt.15982] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 700 |
Ezaj MMA, Junaid M, Akter Y, Nahrin A, Siddika A, Afrose SS, Nayeem SMA, Haque MS, Moni MA, Hosen SMZ. Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy. J Biomol Struct Dyn 2021;:1-26. [PMID: 33586620 DOI: 10.1080/07391102.2021.1886171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 701 |
Almeida A, Faustino MAF, Neves MGPMS. Antimicrobial Photodynamic Therapy in the Control of COVID-19. Antibiotics (Basel) 2020;9:E320. [PMID: 32545171 DOI: 10.3390/antibiotics9060320] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 16.5] [Reference Citation Analysis]
|
| 702 |
Dragojevic Simic V, Miljkovic M, Stamenkovic D, Vekic B, Ratkovic N, Simic R, Rancic N. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. Int J Clin Pract 2021;75:e13825. [PMID: 33156564 DOI: 10.1111/ijcp.13825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 703 |
Wu Y, Feng Z, Li P, Yu Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. Clin Chim Acta. 2020;509:220-223. [PMID: 32562665 DOI: 10.1016/j.cca.2020.06.026] [Cited by in Crossref: 105] [Cited by in F6Publishing: 85] [Article Influence: 52.5] [Reference Citation Analysis]
|
| 704 |
Kumar R, Kumar V, Lee KW. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment. Comput Biol Med 2021;130:104186. [PMID: 33360831 DOI: 10.1016/j.compbiomed.2020.104186] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 705 |
Ni Y, Liao J, Qian Z, Wu C, Zhang X, Zhang J, Xie Y, Jiang S. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro. Bioorg Med Chem 2022;53:116523. [PMID: 34875467 DOI: 10.1016/j.bmc.2021.116523] [Reference Citation Analysis]
|
| 706 |
Ketfi A, Chabati O, Chemali S, Mahjoub M, Gharnaout M, Touahri R, Djenouhat K, Selatni F, Saad HB. Profil clinique, biologique et radiologique des patients Algériens hospitalisés pour COVID-19: données préliminaires. Pan Afr Med J 2020;35:77. [PMID: 33623601 DOI: 10.11604/pamj.supp.2020.35.2.23807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 707 |
Kumar S, Choudhary M. Synthesis and characterization of novel copper( ii ) complexes as potential drug candidates against SARS-CoV-2 main protease. New J Chem . [DOI: 10.1039/d2nj00283c] [Reference Citation Analysis]
|
| 708 |
Wilde AAM, Offerhaus JA. The 'president's drug'. Neth Heart J 2020;28:363-5. [PMID: 32651844 DOI: 10.1007/s12471-020-01441-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 709 |
Almutairi AF, BaniMustafa A, Alessa YM, Almutairi SB, Almaleh Y. Public Trust and Compliance with the Precautionary Measures Against COVID-19 Employed by Authorities in Saudi Arabia. Risk Manag Healthc Policy 2020;13:753-60. [PMID: 32753988 DOI: 10.2147/RMHP.S257287] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 710 |
Rother N, Yanginlar C, Lindeboom RGH, Bekkering S, van Leent MMT, Buijsers B, Jonkman I, de Graaf M, Baltissen M, Lamers LA, Riksen NP, Fayad ZA, Mulder WJM, Hilbrands LB, Joosten LAB, Netea MG, Vermeulen M, van der Vlag J, Duivenvoorden R. Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell Rep Med 2020;1:100146. [PMID: 33377122 DOI: 10.1016/j.xcrm.2020.100146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 711 |
Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, Berrino L, Racagni G, Rossi F, Capuano A. Current pharmacological treatments for COVID-19: What's next? Br J Pharmacol 2020;177:4813-24. [PMID: 32329520 DOI: 10.1111/bph.15072] [Cited by in Crossref: 104] [Cited by in F6Publishing: 82] [Article Influence: 52.0] [Reference Citation Analysis]
|
| 712 |
Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME, Selmi C. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020;109:102442. [PMID: 32253068 DOI: 10.1016/j.jaut.2020.102442] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 32.0] [Reference Citation Analysis]
|
| 713 |
Bonam SR, Muller S, Bayry J, Klionsky DJ. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. Autophagy 2020;16:2260-6. [PMID: 32522067 DOI: 10.1080/15548627.2020.1779467] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 714 |
Al-Romaima A, Liao Y, Feng J, Qin X, Qin G. Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. J Thorac Dis 2020;12:6054-69. [PMID: 33209439 DOI: 10.21037/jtd-20-1810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 715 |
Giaime P, Guenoun M, Pedinielli N, Narbonne H, Bergounioux JP, Solas C, Guilhaumou R, Sampol J, Ollier J, Sichez H, Serveaux M, Brunner F, Bataille S. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. Nephrol Dial Transplant 2020;35:1346-53. [PMID: 32844224 DOI: 10.1093/ndt/gfaa191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 716 |
Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr. 2020;14:251-254. [PMID: 32247213 DOI: 10.1016/j.dsx.2020.03.012] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 28.0] [Reference Citation Analysis]
|
| 717 |
Kim SB, Huh K, Heo JY, Joo EJ, Kim YJ, Choi WS, Kim YJ, Seo YB, Yoon YK, Ku NS, Jeong SJ, Kim SH, Peck KR, Yeom JS. Interim Guidelines on Antiviral Therapy for COVID-19. Infect Chemother 2020;52:281-304. [PMID: 32342676 DOI: 10.3947/ic.2020.52.2.281] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 718 |
Özdemir İH, Özlek B, Özen MB, Gündüz R, Çetin N, Bilge AR. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. Int J Clin Pract 2021;75:e13896. [PMID: 33280207 DOI: 10.1111/ijcp.13896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 719 |
Rogosnitzky M, Berkowitz E, Jadad AR. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. JMIRx Med 2020;1:e19583. [PMID: 33724265 DOI: 10.2196/19583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 720 |
Shah SB, Pahade A, Chawla R. The COVID-19 hydroxychloroquine prophylaxis perception of Indian anesthesiologists: A survey-based original article. J Anaesthesiol Clin Pharmacol 2020;36:471-6. [PMID: 33840926 DOI: 10.4103/joacp.JOACP_379_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 721 |
Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA. Tackling the cytokine storm in COVID-19, challenges and hopes. Life Sci 2020;257:118054. [PMID: 32663575 DOI: 10.1016/j.lfs.2020.118054] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 722 |
Kutsuna S. Coronavirus disease 2019 (COVID-19): research progress and clinical practice. Glob Health Med 2020;2:78-88. [PMID: 33330782 DOI: 10.35772/ghm.2020.01031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 723 |
Bein B, Bachmann M, Huggett S, Wegermann P. [SARS CoV-2/COVID-19: Evidence-Based Recommendation on Diagnosis and Therapy]. Anasthesiol Intensivmed Notfallmed Schmerzther 2020;55:257-65. [PMID: 32274773 DOI: 10.1055/a-1146-8674] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influen |
